Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T-cell	B-protein
interleukin-2	I-protein
expression	O
at	O
the	O
level	O
of	O
purine-box/nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
and	O
NF-kappaB	B-protein
transcriptional	O
activation	O
.	O

PG490	O
(	O
triptolide	O
)	O
is	O
a	O
diterpene	O
triepoxide	O
with	O
potent	O
immunosuppressive	O
and	O
antiinflammatory	O
properties	O
.	O

PG490	O
inhibits	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
expression	O
by	O
normal	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	B-protein
(	O
IC50	O
of	O
10	O
ng/ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng/ml	O
)	O
.	O

In	O
Jurkat	B-cell_line
T-cells	I-cell_line
,	O
PG490	O
inhibits	O
PMA/Iono-stimulated	O
IL-2	B-protein
transcription	O
.	O

PG490	O
inhibits	O
the	O
induction	O
of	O
DNA	O
binding	O
activity	O
at	O
the	O
purine-box/antigen	B-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
ARRE	I-DNA
)	I-DNA
/nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T-cells	I-DNA
(	I-DNA
NF-AT	I-DNA
)	I-DNA
target	I-DNA
sequence	I-DNA
but	O
not	O
at	O
the	O
NF-kappaB	B-DNA
site	I-DNA
.	O

PG490	O
can	O
completely	O
inhibit	O
transcriptional	O
activation	O
at	O
the	O
purine-box/ARRE/NF-AT	B-DNA
and	I-DNA
NF-kappaB	I-DNA
target	I-DNA
DNA	I-DNA
sequences	I-DNA
triggered	O
by	O
all	O
stimuli	O
examined	O
(	O
PMA	O
,	O
PMA/Iono	O
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
)	O
.	O

PG490	O
also	O
inhibits	O
PMA-stimulated	O
activation	O
of	O
a	O
chimeric	B-protein
transcription	I-protein
factor	I-protein
in	O
which	O
the	O
C-terminal	B-protein
TA1	I-protein
transactivation	I-protein
domain	I-protein
of	O
NF-kappaB	B-protein
p65	I-protein
is	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
GAL4	B-protein
.	O

In	O
16HBE	B-cell_type
human	I-cell_type
bronchial	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
IL-8	B-protein
expression	O
is	O
regulated	O
predominantly	O
by	O
NF-kappaB	B-protein
,	O
and	O
PG490	O
but	O
not	O
cyclosporin	O
A	O
can	O
completely	O
inhibit	O
expression	O
of	O
IL-8	B-protein
.	O

The	O
mechanism	O
of	O
PG490	O
inhibition	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
differs	O
from	O
cyclosporin	O
A	O
and	O
involves	O
nuclear	O
inhibition	O
of	O
transcriptional	O
activation	O
of	O
NF-kappaB	B-protein
and	O
the	O
purine-box	B-DNA
regulator	I-DNA
operating	O
at	O
the	O
ARRE/NF-AT	B-DNA
site	I-DNA
at	O
a	O
step	O
after	O
specific	O
DNA	O
binding	O
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

19	NULL
,	NULL
Issue	NULL
of	NULL
May	NULL
7	NULL
,	NULL
pp	NULL
.	NULL

13443-13450	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Immunosuppressant	NULL
PG490	NULL
(	NULL
Triptolide	NULL
)	NULL
Inhibits	NULL
T-cell	NULL
Interleukin-2	NULL
Expression	NULL
at	NULL
the	NULL
Level	NULL
of	NULL
Purine-box/Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T-cells	NULL
and	NULL
NF-KB	NULL
Transcriptional	NULL
Activation*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
July	NULL
6	NULL
,	NULL
1998	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
January	NULL
7	NULL
,	NULL
1999	NULL
)	NULL
Daoming	NULL
Qiu	NULL
,	NULL
Guohua	NULL
Zhao	NULL
,	NULL
Yosuke	NULL
Aoki	NULL
,	NULL
Lingfang	NULL
Shi	NULL
,	NULL
Anne	NULL
Uyei	NULL
,	NULL
Saman	NULL
Nazarian	NULL
,	NULL
James	NULL
C.-H.	NULL
Ng	NULL
,	NULL
and	NULL
Peter	NULL
N.	NULL
Kao	NULL
#	NULL
From	NULL
the	NULL
Pulmonary	NULL
and	NULL
Critical	NULL
Care	NULL
Medicine	NULL
,	NULL
Stanford	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Stanford	NULL
,	NULL
California	NULL
94305-5236	NULL
PGA90	NULL
(	NULL
triptolide	NULL
)	NULL
is	NULL
a	NULL
diterpene	NULL
triepoxide	NULL
with	NULL
potent	NULL
immunosuppressive	NULL
and	NULL
antiinflammatory	NULL
proper-ties	NULL
.	NULL

PG490	NULL
inhibits	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-2	NULL
expression	NULL
by	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
antibody	NULL
to	NULL
CD3	NULL
(	NULL
IC	NULL
;	NULL
,	NULL
of	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Iono	NULL
,	NULL
IC	NULL
;	NULL
,	NULL
of	NULL
40	NULL
ng/ml	NULL
)	NULL
.	NULL

In	NULL
Jurkat	NULL
T-cells	NULL
,	NULL
PG490	NULL
inhibits	NULL
PMA/Iono-stimulated	NULL
IL-2	NULL
transcription	NULL
.	NULL

PG490	NULL
inhibits	NULL
the	NULL
induction	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
at	NULL
the	NULL
purine-box/antigen	NULL
receptor	NULL
response	NULL
element	NULL
(	NULL
ARRE	NULL
)	NULL
/	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T-cells	NULL
(	NULL
NF-AT	NULL
)	NULL
target	NULL
sequence	NULL
but	NULL
not	NULL
at	NULL
the	NULL
NF-B	NULL
site	NULL
.	NULL

PG490	NULL
can	NULL
completely	NULL
inhibit	NULL
transcriptional	NULL
activation	NULL
at	NULL
the	NULL
purine-box/	NULL
ARRE/NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
DNA	NULL
sequences	NULL
triggered	NULL
by	NULL
all	NULL
stimuli	NULL
examined	NULL
(	NULL
PMA	NULL
,	NULL
PMA/Iono	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
)	NULL
.	NULL

PG490	NULL
also	NULL
inhibits	NULL
PMA-stimulated	NULL
activation	NULL
of	NULL
a	NULL
chimeric	NULL
transcription	NULL
factor	NULL
in	NULL
which	NULL
the	NULL
C-terminal	NULL
TAl	NULL
transactivation	NULL
domain	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
is	NULL
fused	NULL
to	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
GAL4	NULL
.	NULL

In	NULL
16HBE	NULL
human	NULL
bronchial	NULL
epithelial	NULL
cells	NULL
,	NULL
IL-8	NULL
expression	NULL
is	NULL
regulated	NULL
predominantly	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
and	NULL
PG490	NULL
but	NULL
not	NULL
cyclosporin	NULL
A	NULL
can	NULL
completely	NULL
inhibit	NULL
expression	NULL
of	NULL
IL-8	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
PG490	NULL
inhibition	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
differs	NULL
from	NULL
cyclosporin	NULL
A	NULL
and	NULL
involves	NULL
nuclear	NULL
inhibition	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
NF-B	NULL
and	NULL
the	NULL
purine-box	NULL
regulator	NULL
operating	NULL
at	NULL
the	NULL
ARRE/	NULL
NF-AT	NULL
site	NULL
at	NULL
a	NULL
step	NULL
after	NULL
specific	NULL
DNA	NULL
binding	NULL
.	NULL

Extracts	NULL
of	NULL
the	NULL
Chinese	NULL
herb	NULL
Tripterygium	NULL
Wilfordii	NULL
hook	NULL
have	NULL
potent	NULL
antiinflammatory	NULL
and	NULL
immunosuppressive	NULL
properties	NULL
and	NULL
have	NULL
been	NULL
used	NULL
successfully	NULL
in	NULL
traditional	NULL
Chinese	NULL
medicine	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
1	NULL
)	NULL
.	NULL

One	NULL
active	NULL
component	NULL
of	NULL
Tripterygium	NULL
extracts	NULL
is	NULL
the	NULL
diterpene	NULL
triepoxide	NULL
,	NULL
triptolide	NULL
,	NULL
which	NULL
possesses	NULL
antileukemic	NULL
activities	NULL
(	NULL
2	NULL
)	NULL
and	NULL
also	NULL
inhibits	NULL
proliferation	NULL
of	NULL
transformed	NULL
cell	NULL
lines	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Kupchan	NULL
and	NULL
Shubert	NULL
(	NULL
5	NULL
)	NULL
described	NULL
that	NULL
triptolide	NULL
possesses	NULL
a	NULL
9,11-epoxy-14B-hydroxy	NULL
system	NULL
,	NULL
which	NULL
is	NULL
important	NULL
for	NULL
bio-logic	NULL
activity	NULL
,	NULL
and	NULL
proposed	NULL
that	NULL
this	NULL
system	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
selective	NULL
alkylation	NULL
by	NULL
nucleophilic	NULL
groups	NULL
such	NULL
as	NULL
thiols	NULL
present	NULL
in	NULL
key	NULL
target	NULL
enzymes	NULL
involved	NULL
in	NULL
growth	NULL
regulation	NULL
.	NULL

A	NULL
refined	NULL
extract	NULL
of	NULL
Tripterygium	NULL
,	NULL
PG27	NULL
,	NULL
which	NULL
contains	NULL
PG490	NULL
(	NULL
triptolide	NULL
)	NULL
as	NULL
its	NULL
active	NULL
compound	NULL
,	NULL
prolongs	NULL
heart	NULL
and	NULL
kidney	NULL
allograft	NULL
survival	NULL
in	NULL
rat	NULL
transplantation	NULL
models	NULL
and	NULL
,	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
RO01-AI89624	NULL
and	NULL
K04-01147	NULL
(	NULL
to	NULL
P.	NULL
N.	NULL
K.	NULL
)	NULL
,	NULL
and	NULL
gifts	NULL
from	NULL
the	NULL
Donald	NULL
E.	NULL
and	NULL
Delia	NULL
B.	NULL
Baxter	NULL
Foundation	NULL
and	NULL
Pharmagenesis	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.9.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
650-725-0570	NULL
;	NULL
Fax	NULL
:	NULL
650-725-5489	NULL
;	NULL
E-mail	NULL
:	NULL
peterkao	NULL
@	NULL
leland.stanford.edu	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
furthermore	NULL
,	NULL
displays	NULL
synergy	NULL
with	NULL
the	NULL
immunosuppressant	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
in	NULL
preventing	NULL
cardiac	NULL
and	NULL
renal	NULL
allotrans-plant	NULL
rejection	NULL
.	NULL
``	NULL

The	NULL
combination	NULL
of	NULL
PG27	NULL
with	NULL
CsA	NULL
substantially	NULL
prolongs	NULL
hamster	NULL
cardiac	NULL
xenograft	NULL
survival	NULL
in	NULL
rat	NULL
recipients	NULL
and	NULL
inhibits	NULL
the	NULL
production	NULL
of	NULL
serum	NULL
anti-hamster	NULL
IgM	NULL
and	NULL
IgG	NULL
xenoantibodies	NULL
where	NULL
single	NULL
drug	NULL
therapies	NULL
are	NULL
inef-fective	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
PG27	NULL
suppresses	NULL
the	NULL
development	NULL
of	NULL
graft	NULL
versus	NULL
host	NULL
disease	NULL
associated	NULL
with	NULL
allogeneic	NULL
bone	NULL
marrow	NULL
transplantation	NULL
.	NULL
``	NULL

The	NULL
chloroform	NULL
methanol	NULL
extract	NULL
of	NULL
Triptyer-gium	NULL
,	NULL
T2	NULL
(	NULL
6	NULL
)	NULL
,	NULL
has	NULL
been	NULL
studied	NULL
recently	NULL
(	NULL
7-9	NULL
)	NULL
and	NULL
was	NULL
shown	NULL
to	NULL
block	NULL
mitogen-induced	NULL
early	NULL
cytokine	NULL
gene	NULL
transcription	NULL
in	NULL
T-cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

An	NULL
early	NULL
cytokine	NULL
transcribed	NULL
during	NULL
T-cell	NULL
activation	NULL
is	NULL
IL-2	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

11	NULL
)	NULL
.	NULL

IL-2	NULL
transcription	NULL
involves	NULL
specific	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activation	NULL
of	NULL
a	NULL
purine-box	NULL
transcriptional	NULL
regulator	NULL
operative	NULL
at	NULL
the	NULL
antigen	NULL
receptor	NULL
response	NULL
element	NULL
(	NULL
ARRE	NULL
)	NULL
/NF-AT	NULL
target	NULL
DNA	NULL
sequence	NULL
,	NULL
and	NULL
of	NULL
NF-kB	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
Oct-1	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

11	NULL
)	NULL
.	NULL

The	NULL
T-cell	NULL
immunosup-pressants	NULL
,	NULL
CsA	NULL
and	NULL
FK506	NULL
,	NULL
inhibit	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
through	NULL
mechanisms	NULL
that	NULL
may	NULL
involve	NULL
the	NULL
serine/threo-nine	NULL
protein	NULL
phosphatase	NULL
,	NULL
calcineurin	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

11	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
interfere	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
activity	NULL
at	NULL
the	NULL
purine-box/	NULL
ARRE/NF-AT	NULL
target	NULL
DNA	NULL
sequence	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

11	NULL
)	NULL
.	NULL

We	NULL
previously	NULL
purified	NULL
to	NULL
homogeneity	NULL
a	NULL
CsA-	NULL
and	NULL
FK506-sensitive	NULL
sequence-specific	NULL
purine-box	NULL
DNA	NULL
binding	NULL
complex	NULL
that	NULL
contains	NULL
NF45	NULL
and	NULL
NF90	NULL
proteins	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
NF45	NULL
and	NULL
NF9O0	NULL
associate	NULL
tightly	NULL
with	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
DNA-dependent	NULL
protein	NULL
kinase	NULL
and	NULL
serve	NULL
to	NULL
stabilize	NULL
the	NULL
association	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
DNA-dependent	NULL
protein	NULL
kinase	NULL
with	NULL
DNA-targeting	NULL
proteins	NULL
,	NULL
Ku80	NULL
and	NULL
Ku70	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
catalytic	NULL
subunit	NULL
of	NULL
DNA-dependent	NULL
protein	NULL
kinase	NULL
and	NULL
Ku	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
with	NULL
sequence	NULL
specificity	NULL
to	NULL
purine-rich	NULL
target	NULL
DNA	NULL
sequences	NULL
and	NULL
to	NULL
mediate	NULL
sequence-specific	NULL
transcriptional	NULL
repression	NULL
(	NULL
15	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
the	NULL
specific	NULL
CsA-sensitive	NULL
purine-box/ARRE	NULL
DNA	NULL
binding	NULL
complex	NULL
in	NULL
human	NULL
bronchial	NULL
epithelial	NULL
cells	NULL
involves	NULL
NF45	NULL
,	NULL
NF90	NULL
,	NULL
Ku80	NULL
,	NULL
and	NULL
Ku70	NULL
with	NULL
no	NULL
evidence	NULL
for	NULL
NF-ATp	NULL
or	NULL
NF-ATce	NULL
proteins	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
IL-2	NULL
transcription	NULL
triggered	NULL
through	NULL
costimu-	NULL
*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
ARRE	NULL
,	NULL
antigen	NULL
receptor	NULL
response	NULL
element	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
GAPDH	NULL
,	NULL
glyceraldehyde	NULL
phosphate	NULL
dehydrogenase	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
Tono	NULL
,	NULL
ionomycin	NULL
;	NULL
NF-AT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T-cells	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
PG490	NULL
,	NULL
Pharmagenesis	NULL
490	NULL
,	NULL
97	NULL
%	NULL
pure	NULL
triptolide	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
RLU	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
;	NULL
IFN	NULL
,	NULL
interferon	NULL
;	NULL
P/I	NULL
,	NULL
PMA	NULL
+	NULL
ionomycin	NULL
;	NULL
ELISA	NULL
,	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
;	NULL
NS	NULL
,	NULL
nonstimulated	NULL
.	NULL

*	NULL
J.	NULL
Fidler	NULL
,	NULL
Pharmagenesis	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
,	NULL
unpublished	NULL
data	NULL
.	NULL

*	NULL
N.	NULL
Chao	NULL
,	NULL
Duke	NULL
University	NULL
,	NULL
and	NULL
J.	NULL
Fidler	NULL
,	NULL
Pharmagenesis	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
,	NULL
unpublished	NULL
data	NULL
.	NULL

13443	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
13444	NULL
latory	NULL
receptors	NULL
such	NULL
as	NULL
CD28	NULL
involves	NULL
NF-kB	NULL
(	NULL
17	NULL
)	NULL
and	NULL
is	NULL
largely	NULL
resistant	NULL
to	NULL
inhibition	NULL
by	NULL
CsA	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
transcription	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
involves	NULL
stimulation-induced	NULL
degradation	NULL
of	NULL
I	NULL
«	NULL
B	NULL
,	NULL
which	NULL
serves	NULL
to	NULL
release	NULL
NF	NULL
-B	NULL
p65	NULL
for	NULL
translocation	NULL
from	NULL
the	NULL
cytoplasm	NULL
into	NULL
the	NULL
nucleus	NULL
.	NULL

In	NULL
the	NULL
nucleus	NULL
,	NULL
p65	NULL
binds	NULL
as	NULL
a	NULL
heterodimer	NULL
to	NULL
its	NULL
target	NULL
DNA	NULL
sequence	NULL
and	NULL
then	NULL
interacts	NULL
with	NULL
transcriptional	NULL
regulatory	NULL
components	NULL
to	NULL
signal	NULL
initiation	NULL
of	NULL
transcription	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

19	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
signaling	NULL
is	NULL
regulated	NULL
by	NULL
phosphorylation	NULL
in	NULL
the	NULL
cytoplasm	NULL
at	NULL
the	NULL
level	NULL
of	NULL
IB	NULL
in	NULL
the	NULL
nucleus	NULL
at	NULL
the	NULL
level	NULL
of	NULL
specific	NULL
DNA	NULL
binding	NULL
and	NULL
also	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
activation	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

20	NULL
)	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
immunosuppressive	NULL
and	NULL
antiinfiamma-tory	NULL
properties	NULL
of	NULL
PG490	NULL
(	NULL
pure	NULL
triptolide	NULL
)	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
,	NULL
Jurkat	NULL
T-cells	NULL
,	NULL
and	NULL
human	NULL
bronchial	NULL
epithelial	NULL
cells	NULL
and	NULL
show	NULL
that	NULL
the	NULL
mechanism	NULL
of	NULL
inhibition	NULL
by	NULL
PGA49O0	NULL
differs	NULL
fundamentally	NULL
from	NULL
that	NULL
of	NULL
CsA	NULL
and	NULL
involves	NULL
inhibition	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
purine-box	NULL
regulator	NULL
of	NULL
the	NULL
ARRE/NF-AT	NULL
site	NULL
and	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
at	NULL
a	NULL
step	NULL
after	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Source	NULL
of	NULL
Triptolide-PG490	NULL
(	NULL
triptolide	NULL
,	NULL
molecular	NULL
weight	NULL
860	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Pharmagenesis	NULL
(	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
material	NULL
was	NULL
composed	NULL
of	NULL
white	NULL
to	NULL
off-white	NULL
crystals	NULL
,	NULL
had	NULL
a	NULL
melting	NULL
point	NULL
of	NULL
226-240	NULL
°C	NULL
,	NULL
conformed	NULL
to	NULL
standard	NULL
triptolide	NULL
preparation	NULL
by	NULL
proton	NULL
nuclear	NULL
magnetic	NULL
resonance	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
was	NULL
97	NULL
%	NULL
pure	NULL
by	NULL
reverse	NULL
phase	NULL
high	NULL
pressure	NULL
liquid	NULL
chromatography	NULL
evaluation	NULL
using	NULL
acetonitrile	NULL
:	NULL
methanol	NULL
:	NULL
water	NULL
(	NULL
18:9:78	NULL
)	NULL
.+	NULL
Cell	NULL
Culture	NULL
and	NULL
Stimulation	NULL
Conditions-Human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBL	NULL
)	NULL
were	NULL
prepared	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
gradient	NULL
of	NULL
sodium	NULL
diatrizoate/Ficoll	NULL
(	NULL
Sigma	NULL
)	NULL
of	NULL
a	NULL
buffy	NULL
coat	NULL
obtained	NULL
from	NULL
the	NULL
Stanford	NULL
Hospital	NULL
blood	NULL
bank	NULL
.	NULL

Monocytes	NULL
were	NULL
depleted	NULL
by	NULL
adherence	NULL
to	NULL
plastic	NULL
culture	NULL
dishes	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
then	NULL
the	NULL
PBLs	NULL
were	NULL
stimulated	NULL
for	NULL
12	NULL
h	NULL
at	NULL
a	NULL
density	NULL
of	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
(	NULL
clone	NULL
E6G-1	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Manas-sas	NULL
,	NULL
VA	NULL
)	NULL
,	NULL
and	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Mediatech	NULL
,	NULL
Herndon	NULL
,	NULL
VA	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
and	NULL
100	NULL
mg/ml	NULL
streptomycin	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

An	NULL
SV-40	NULL
large	NULL
T-antigen	NULL
transformed	NULL
human	NULL
bronchial	NULL
epithelial	NULL
cell	NULL
line	NULL
16HBE1l4o-	NULL
(	NULL
16HBE	NULL
)	NULL
,	NULL
which	NULL
retains	NULL
differentiated	NULL
morphology	NULL
and	NULL
function	NULL
of	NULL
normal	NULL
human	NULL
airway	NULL
epithelia	NULL
(	NULL
21	NULL
)	NULL
,	NULL
was	NULL
cultured	NULL
in	NULL
Eagle	NULL
's	NULL
minimum	NULL
essential	NULL
medium	NULL
(	NULL
BioWhittaker	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
and	NULL
100	NULL
mg/ml	NULL
streptomycin	NULL
(	NULL
BioWhittaker	NULL
)	NULL
as	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Human	NULL
PBLs	NULL
,	NULL
Jurkat	NULL
T-cells	NULL
,	NULL
or	NULL
monolayer	NULL
16HBE	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
in	NULL
culture	NULL
media	NULL
containing	NULL
20	NULL
ng/ml	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
;	NULL
Calbiochem	NULL
)	NULL
,	NULL
PMA	NULL
+	NULL
antibody	NULL
to	NULL
CD3	NULL
(	NULL
clone	NULL
HIT3a	NULL
,	NULL
Pharmingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
PMA	NULL
+	NULL
antibody	NULL
to	NULL
CD28	NULL
(	NULL
Y¥TH918.12	NULL
,	NULL
BIOSOURCE	NULL
,	NULL
Camarillo	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
PMA	NULL
+	NULL
2	NULL
pM	NULL
ionomycin	NULL
(	NULL
Iono	NULL
;	NULL
Calbiochem	NULL
)	NULL
,	NULL
or	NULL
20	NULL
ng/ml	NULL
TNF-a	NULL
(	NULL
BIOSOURCE	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PG490	NULL
,	NULL
CsA	NULL
(	NULL
Sandoz	NULL
)	NULL
,	NULL
or	NULL
FK506	NULL
(	NULL
Fujisawa	NULL
)	NULL
.	NULL

RNA	NULL
Extraction	NULL
and	NULL
Northern	NULL
Analyses-Total	NULL
RNA	NULL
was	NULL
isolated	NULL
and	NULL
analyzed	NULL
by	NULL
Northern	NULL
hybridization	NULL
as	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Complementary	NULL
DNA	NULL
probes	NULL
for	NULL
human	NULL
IL-2	NULL
(	NULL
788	NULL
bp	NULL
)	NULL
.	NULL

IL-8	NULL
(	NULL
289	NULL
bp	NULL
)	NULL
,	NULL
IxBa	NULL
(	NULL
888	NULL
bp	NULL
)	NULL
,	NULL
NF90	NULL
(	NULL
2,008	NULL
bp	NULL
)	NULL
,	NULL
and	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
;	NULL
0.6-kilobase	NULL
Xbal-HindIII	NULL
fragment	NULL
of	NULL
cDNA	NULL
)	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
a-	NULL
``	NULL
``	NULL
PIdCTP	NULL
using	NULL
a	NULL
random	NULL
hexamer	NULL
labeling	NULL
kit	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

Nuclear	NULL
Extract	NULL
Preparation	NULL
and	NULL
Electrophoretic	NULL
Mobility	NULL
Shift	NULL
As-says-Jurkat	NULL
T-cells	NULL
were	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
,	NULL
pelleted	NULL
,	NULL
and	NULL
washed	NULL
,	NULL
and	NULL
cytosolic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
from	NULL
chromatin	NULL
using	NULL
0.3	NULL
M	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
,50	NULL
,	NULL
,	NULL
and	NULL
then	NULL
soluble	NULL
nuclear	NULL
proteins	NULL
were	NULL
precipitated	NULL
using	NULL
1.5	NULL
M	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
,580	NULL
,	NULL
,	NULL
followed	NULL
by	NULL
dialysis	NULL
into	NULL
DNA	NULL
binding	NULL
buffer	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Transcription	NULL
factor	NULL
DNA	NULL
binding	NULL
activities	NULL
in	NULL
Jurkat	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
were	NULL
assayed	NULL
using	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

10	NULL
ug	NULL
of	NULL
nuclear	NULL
proteins	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
25	NULL
°C	NULL
in	NULL
20	NULL
pl	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
25	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
0.05	NULL
mM	NULL
dithiothreitol	NULL
)	NULL
containing	NULL
1-2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
2.5	NULL
pg	NULL
of	NULL
*°P-labeled	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
approxi-	NULL
*	NULL
J.	NULL
Fidler	NULL
and	NULL
R.-L.	NULL
Jin	NULL
,	NULL
Pharmagenesis	NULL
,	NULL
private	NULL
communication	NULL
.	NULL

PG490	NULL
Inhibits	NULL
Purine-box	NULL
/	NULL
NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Transcription	NULL
mately	NULL
1	NULL
X	NULL
10°	NULL
cpm	NULL
)	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
oligonucleotide	NULL
probes	NULL
used	NULL
were	NULL
agctAAAGAGGGACTTTCCCTAAA	NULL
for	NULL
the	NULL
immunoglobulin	NULL
x	NULL
light	NULL
chain	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
(	NULL
19	NULL
)	NULL
,	NULL
and	NULL
aagaAAGGAGGAAAAACTGTTTCATA	NULL
(	NULL
-259	NULL
to	NULL
-284	NULL
in	NULL
the	NULL
human	NULL
IL-2	NULL
enhancer	NULL
)	NULL
for	NULL
the	NULL
purine-box/NF-AT	NULL
site	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Probes	NULL
were	NULL
labeled	NULL
by	NULL
filling	NULL
in	NULL
overhanging	NULL
ends	NULL
(	NULL
identified	NULL
by	NULL
lowercase	NULL
letters	NULL
)	NULL
using	NULL
Klenow	NULL
DNA	NULL
polymerase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
and	NULL
[	NULL
a-*°P	NULL
]	NULL
dCTP	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
,	NULL
and	NULL
nonra-dioactive	NULL
dGTP	NULL
,	NULL
dATP	NULL
,	NULL
and	NULL
dTTP	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
resolved	NULL
from	NULL
free	NULL
probe	NULL
using	NULL
4	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
0.5	NULL
%	NULL
Tris	NULL
borate	NULL
EDTA	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
and	NULL
visualized	NULL
by	NULL
fluorography	NULL
.	NULL

Plasmids	NULL
,	NULL
Transfections	NULL
,	NULL
and	NULL
Luciferase	NULL
Reporter	NULL
Gene	NULL
Assays-Lu-ciferase	NULL
reporter	NULL
gene	NULL
constructs	NULL
were	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
nucleotides	NULL
-826	NULL
to	NULL
+48	NULL
,	NULL
pCLN15deltaCX	NULL
,	NULL
prepared	NULL
by	NULL
D.	NULL
Durand	NULL
,	NULL
Stanford	NULL
University	NULL
)	NULL
,	NULL
or	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
purine-box/NF-AT	NULL
regulatory	NULL
sequence	NULL
sequence	NULL
(	NULL
-285	NULL
to	NULL
-255	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
enhancer	NULL
)	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
,	NULL
or	NULL
the	NULL
immunoglobulin	NULL
x	NULL
light	NULL
chain	NULL
NF-kB	NULL
sequence	NULL
monomer	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
minimal	NULL
IL-8	NULL
promoter	NULL
(	NULL
-45	NULL
to	NULL
+40	NULL
of	NULL
the	NULL
human	NULL
IL-8	NULL
promoter	NULL
)	NULL
.	NULL

These	NULL
plasmids	NULL
also	NULL
contain	NULL
a	NULL
neomycin	NULL
resistance	NULL
gene	NULL
under	NULL
control	NULL
of	NULL
the	NULL
constitutively	NULL
active	NULL
SV40	NULL
promoter	NULL
,	NULL
and	NULL
this	NULL
allows	NULL
G418	NULL
antibiotic	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
selection	NULL
of	NULL
cell	NULL
lines	NULL
that	NULL
stably	NULL
express	NULL
the	NULL
luciferase	NULL
reporter	NULL
constructs	NULL
.	NULL

The	NULL
GAL4-luciferase	NULL
reporter	NULL
contains	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
GAL4	NULL
target	NULL
DNA	NULL
sequence	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
and	NULL
was	NULL
prepared	NULL
by	NULL
J.	NULL
Riegel	NULL
at	NULL
Stanford	NULL
University	NULL
.	NULL

For	NULL
normalizing	NULL
the	NULL
transient	NULL
transfection	NULL
assays	NULL
,	NULL
plasmid	NULL
pEF	NULL
Renilla	NULL
luciferase	NULL
was	NULL
generated	NULL
by	NULL
cloning	NULL
the	NULL
elongation	NULL
factor	NULL
1	NULL
«	NULL
promoter	NULL
(	NULL
28	NULL
)	NULL
into	NULL
the	NULL
pRL	NULL
null	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
between	NULL
the	NULL
EcoRI	NULL
and	NULL
HindIII	NULL
sites	NULL
.	NULL

Expression	NULL
plasmids	NULL
pEF	NULL
CNA	NULL
and	NULL
pEF	NULL
CNB	NULL
contain	NULL
the	NULL
elongation	NULL
factor	NULL
l	NULL
«	NULL
promoter	NULL
(	NULL
23	NULL
)	NULL
upstream	NULL
of	NULL
rat	NULL
calcineurin	NULL
A	NULL
and	NULL
calcineurin	NULL
B	NULL
cDNAs	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Expression	NULL
plasmids	NULL
GAL4p65TAl	NULL
and	NULL
GAL4p65	NULL
{	NULL
TA1+TA2	NULL
}	NULL
utilize	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter	NULL
to	NULL
drive	NULL
expression	NULL
of	NULL
a	NULL
chimeric	NULL
protein	NULL
with	NULL
the	NULL
GAL4	NULL
DNA	NULL
binding	NULL
domain	NULL
(	NULL
amino	NULL
acids	NULL
1-147	NULL
)	NULL
fused	NULL
to	NULL
the	NULL
p65	NULL
transactivating	NULL
domains	NULL
and	NULL
were	NULL
generated	NULL
by	NULL
Schmitz	NULL
and	NULL
Baeuerle	NULL
(	NULL
25	NULL
)	NULL
and	NULL
obtained	NULL
through	NULL
A.	NULL
Baldwin	NULL
(	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
,	NULL
Chapel	NULL
Hill	NULL
)	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
reporter	NULL
and	NULL
expression	NULL
plasmids	NULL
as	NULL
described	NULL
(	NULL
18	NULL
,	NULL
26	NULL
)	NULL
.	NULL

T-cells	NULL
were	NULL
stimulated	NULL
for	NULL
6-12	NULL
h	NULL
(	NULL
24	NULL
h	NULL
after	NULL
electroporation	NULL
in	NULL
the	NULL
case	NULL
of	NULL
transient	NULL
transfections	NULL
)	NULL
and	NULL
then	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
.	NULL

Cell	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
50	NULL
pl	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.1	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8.0	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
then	NULL
the	NULL
cell	NULL
lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
13,000	NULL
rpm	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
collected	NULL
as	NULL
whole	NULL
cell	NULL
extracts	NULL
,	NULL
and	NULL
the	NULL
Bradford	NULL
reagent	NULL
(	NULL
Bio-Rad	NULL
)	NULL
was	NULL
used	NULL
to	NULL
measure	NULL
protein	NULL
concentration	NULL
.	NULL

20	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
mixed	NULL
with	NULL
200	NULL
ul	NULL
of	NULL
luciferase	NULL
reaction	NULL
mixtures	NULL
(	NULL
1	NULL
mg/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
5	NULL
mM	NULL
ATP	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
25	NULL
mM	NULL
glycylglycine	NULL
,	NULL
and	NULL
15	NULL
mm	NULL
MgSO	NULL
,	NULL
)	NULL
and	NULL
100	NULL
pl	NULL
of	NULL
1	NULL
mM	NULL
D-luciferin	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Triplicate	NULL
determinations	NULL
of	NULL
luminescence	NULL
were	NULL
each	NULL
read	NULL
for	NULL
20	NULL
s	NULL
using	NULL
a	NULL
Monolight	NULL
``	NULL
*	NULL
``	NULL
2010	NULL
luminometer	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
Laborato-ry	NULL
)	NULL
,	NULL
and	NULL
were	NULL
measured	NULL
in	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
RLU	NULL
)	NULL
.	NULL

In	NULL
transient	NULL
transfection	NULL
experiments	NULL
that	NULL
incorporated	NULL
the	NULL
pEF	NULL
Renilla	NULL
luciferase	NULL
normalizing	NULL
plasmid	NULL
,	NULL
20-ul	NULL
aliquots	NULL
of	NULL
whole	NULL
cell	NULL
extracts	NULL
were	NULL
analyzed	NULL
sequentially	NULL
for	NULL
firefly	NULL
and	NULL
Renilla	NULL
luciferase	NULL
activities	NULL
using	NULL
a	NULL
dual	NULL
luciferase	NULL
assay	NULL
kit	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
the	NULL
ratio	NULL
of	NULL
firefly	NULL
to	NULL
Renilla	NULL
RLU	NULL
was	NULL
taken	NULL
to	NULL
represent	NULL
the	NULL
normalized	NULL
(	NULL
firefly	NULL
)	NULL
luciferase	NULL
activity	NULL
.	NULL

Western	NULL
Immunoblotting-Cytosolic	NULL
extracts	NULL
(	NULL
10	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
were	NULL
fractionated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
8	NULL
%	NULL
separating	NULL
gel	NULL
)	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
(	NULL
Schleicher	NULL
and	NULL
Schuell	NULL
)	NULL
.	NULL

IxBa	NULL
was	NULL
detected	NULL
using	NULL
rabbit	NULL
polyclonal	NULL
IgG	NULL
primary	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
at	NULL
1:500	NULL
dilution	NULL
for	NULL
2	NULL
h	NULL
at	NULL
87	NULL
°C	NULL
and	NULL
horseradish	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-rabbit	NULL
secondary	NULL
antibody	NULL
at	NULL
1:3,000	NULL
dilution	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Detection	NULL
was	NULL
with	NULL
enhanced	NULL
chemiluminsescence	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
directions	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

Data	NULL
and	NULL
Statistical	NULL
Analysis-Significance	NULL
of	NULL
the	NULL
differences	NULL
between	NULL
the	NULL
experimental	NULL
conditions	NULL
were	NULL
determined	NULL
by	NULL
paired	NULL
two	NULL
sample	NULL
Student	NULL
's	NULL
£	NULL
test	NULL
(	NULL
Microsoft	NULL
EXCEL	NULL
)	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
are	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

RESULTS	NULL
PG490	NULL
Inhibits	NULL
IL-2	NULL
Expression	NULL
by	NULL
Normal	NULL
Human	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes-PGA4A90	NULL
potently	NULL
inhibits	NULL
IL-2	NULL
expression	NULL
by	NULL
human	NULL
PBLs	NULL
stimulated	NULL
by	NULL
PMA	NULL
+	NULL
anti-CD3	NULL
(	NULL
PMA/	NULL
«	NULL
CD3	NULL
,	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
rows	NULL
5-8	NULL
versus	NULL
row	NULL
4	NULL
)	NULL
,	NULL
and	NULL
by	NULL
PMA	NULL
+	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
rows	NULL
15-17	NULL
versus	NULL
row	NULL
14	NULL
)	NULL
.	NULL

The	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
PG490	NULL
inhibition	NULL
of	NULL
PMA/aCD3-stimulated	NULL
IL-2	NULL
expression	NULL
is	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
PG490	NULL
Inhibits	NULL
Purine-box	NULL
/	NULL
NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Transcription	NULL
ins	NULL
I	NULL
2acp3	NULL
__	NULL
9	NULL
``	NULL
3P	NULL
4	NULL
aCDNP	NULL
5	NULL
«	NULL
CD3/P/PGA490	NULL
4	NULL
6	NULL
aCD3/P/PGA430	NULL
20	NULL
7	NULL
aCD3/P/PGA490	NULL
200	NULL
9	NULL
aCD3/P/CsA	NULL
40	NULL
10	NULL
aCD3/P/CsA	NULL
200	NULL
11	NULL
aCD3/P/CsA	NULL
1000	NULL
121	NULL
13	NULL
VPG490	NULL
4	NULL
14	NULL
PA	NULL
15	NULL
PMPG490	NULL
20	NULL
16	NULL
P/PG490	NULL
200	NULL
17	NULL
P/PG430	NULL
1000	NULL
18	NULL
P/CsA	NULL
1000	NULL
0	NULL
10000	NULL
20000	NULL
Secreted	NULL
IL-2	NULL
(	NULL
pg/ml	NULL
)	NULL
B	NULL
=	NULL
B	NULL
a	NULL
=	NULL
a	NULL
5	NULL
0	NULL
am	NULL
wam	NULL
l	NULL
g_	NULL
g5g	NULL
(	NULL
ng/ml	NULL
)	NULL
&	NULL
&	NULL
-	NULL
ﬁggi	NULL
s.s5	NULL
$	NULL
:	NULL
ffs	NULL
f	NULL
IL-2	NULL
|	NULL
b	NULL
-	NULL
#	NULL
Hp	NULL
or-NFS	NULL
nitri	NULL
``	NULL
ww0	NULL
.	NULL

‘	NULL
a	NULL
capo	NULL
ty	NULL
b	NULL
wy	NULL
I	NULL
Wow	NULL
us	NULL
Wt	NULL
W	NULL
Y	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

PG490	NULL
inhibition	NULL
of	NULL
T-cell	NULL
expression	NULL
of	NULL
IL-2	NULL
.	NULL

A	NULL
,	NULL
PGA490	NULL
inhibits	NULL
IL-2	NULL
expression	NULL
by	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBL	NULL
)	NULL
stimulated	NULL
with	NULL
PMA	NULL
,	NULL
«	NULL
CD3	NULL
,	NULL
and	NULL
with	NULL
P/L	NULL
.	NULL

B	NULL
,	NULL
PG490	NULL
inhibits	NULL
Jurkat	NULL
T-cell	NULL
expression	NULL
of	NULL
IL-2	NULL
protein	NULL
(	NULL
panel	NULL
a	NULL
)	NULL
,	NULL
IL-2	NULL
mRNA	NULL
(	NULL
panel	NULL
b	NULL
)	NULL
and	NULL
IxBa	NULL
mRNA	NULL
(	NULL
panel	NULL
c	NULL
)	NULL
,	NULL
and	NULL
increases	NULL
expression	NULL
of	NULL
NF9O	NULL
mRNA	NULL
(	NULL
panel	NULL
d	NULL
)	NULL
with	NULL
no	NULL
changes	NULL
of	NULL
GAPDH	NULL
mRNA	NULL
(	NULL
panel	NULL
e	NULL
)	NULL
.	NULL

Normal	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
or	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
stimulated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
P	NULL
)	NULL
(	NULL
20	NULL
ng/m1	NULL
)	NULL
,	NULL
anti-CD3	NULL
(	NULL
@	NULL
CD3	NULL
,	NULL
clone	NULL
HIT3a	NULL
,	NULL
10	NULL
ug/ml	NULL
in	NULL
solution	NULL
,	NULL
Pharmingen	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
F	NULL
)	NULL
(	NULL
2	NULL
pM	NULL
)	NULL
,	NULL
P/aCD3	NULL
,	NULL
or	NULL
P/I	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
PG490	NULL
or	NULL
CsA	NULL
.	NULL

Cell	NULL
supernatants	NULL
were	NULL
assayed	NULL
for	NULL
IL-2	NULL
by	NULL
ELISA	NULL
(	NULL
Immunotech	NULL
,	NULL
West-brook	NULL
,	NULL
ME	NULL
)	NULL
,	NULL
and	NULL
Jurkat	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
fractionated	NULL
and	NULL
analyzed	NULL
by	NULL
Northern	NULL
hybridization	NULL
.	NULL

The	NULL
PBL-IL-2-ELISA	NULL
data	NULL
represent	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

from	NULL
four	NULL
independent	NULL
experiments	NULL
;	NULL
statistically	NULL
significant	NULL
inhibitions	NULL
compared	NULL
with	NULL
no	NULL
drug	NULL
treatment	NULL
are	NULL
indicated	NULL
(	NULL
*p	NULL
<	NULL
0.05	NULL
;	NULL
**p	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

approximately	NULL
10	NULL
ng/ml	NULL
(	NULL
28	NULL
nm	NULL
)	NULL
.	NULL

PG490	NULL
at	NULL
200	NULL
ng/ml	NULL
(	NULL
560	NULL
nm	NULL
)	NULL
causes	NULL
more	NULL
complete	NULL
inhibition	NULL
of	NULL
PMA/aCD3-stimulated	NULL
IL-2	NULL
expression	NULL
than	NULL
CsA	NULL
at	NULL
1,000	NULL
ng/ml	NULL
(	NULL
832	NULL
nm	NULL
,	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
row	NULL
7	NULL
versus	NULL
row	NULL
11	NULL
)	NULL
.	NULL

lonomycin	NULL
stimulation	NULL
alone	NULL
causes	NULL
minimal	NULL
induction	NULL
of	NULL
IL-2	NULL
expression	NULL
,	NULL
which	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
lowest	NULL
dose	NULL
of	NULL
4	NULL
ng/ml	NULL
PG490	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
rows	NULL
12	NULL
and	NULL
13	NULL
)	NULL
.	NULL

The	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
PG490	NULL
inhibition	NULL
of	NULL
PMA/Iono-stimulated	NULL
IL-2	NULL
expression	NULL
is	NULL
approximately	NULL
40	NULL
ng/ml	NULL
(	NULL
112	NULL
nm	NULL
)	NULL
.	NULL

PG490	NULL
Inhibits	NULL
Jurkat	NULL
T-Cell	NULL
Cytokine	NULL
and	NULL
Cytokine	NULL
Regulator	NULL
Gene	NULL
Expression	NULL
Differently	NULL
Than	NULL
CsA-Similar	NULL
to	NULL
the	NULL
result	NULL
in	NULL
human	NULL
PBLs	NULL
,	NULL
we	NULL
show	NULL
that	NULL
PG490	NULL
potently	NULL
inhibits	NULL
Jurkat	NULL
T-cell	NULL
expression	NULL
of	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
a	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
PMA/Iono	NULL
bypasses	NULL
membrane	NULL
signaling	NULL
events	NULL
of	NULL
T-cell	NULL
activation	NULL
(	NULL
27	NULL
)	NULL
and	NULL
strongly	NULL
induces	NULL
IL-2	NULL
protein	NULL
and	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panels	NULL
a	NULL
and	NULL
b	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

PGA490	NULL
at	NULL
20	NULL
ng/ml	NULL
(	NULL
56	NULL
nM	NULL
)	NULL
causes	NULL
over	NULL
80	NULL
%	NULL
inhibition	NULL
of	NULL
PMA/Iono-stimulated	NULL
IL-2	NULL
protein	NULL
and	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
a	NULL
and	NULL
b	NULL
,	NULL
lane	NULL
13445	NULL
7	NULL
versus	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

PG490	NULL
at	NULL
200	NULL
ng/ml	NULL
more	NULL
completely	NULL
suppresses	NULL
Jurkat	NULL
T-cell	NULL
IL-2	NULL
protein	NULL
and	NULL
mRNA	NULL
expression	NULL
stimulated	NULL
by	NULL
PMA	NULL
and	NULL
by	NULL
PMA/Iono	NULL
than	NULL
1,000	NULL
ng/ml	NULL
of	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panels	NULL
a	NULL
and	NULL
b	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
versus	NULL
lane	NULL
2	NULL
,	NULL
and	NULL
lanes	NULL
8	NULL
and	NULL
10	NULL
versus	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Using	NULL
Northern	NULL
hybridization	NULL
analysis	NULL
,	NULL
we	NULL
show	NULL
that	NULL
PG490	NULL
has	NULL
distinct	NULL
effects	NULL
on	NULL
the	NULL
mRNA	NULL
expression	NULL
of	NULL
cytokine	NULL
regulators	NULL
IxBa	NULL
and	NULL
NF9O	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panels	NULL
c	NULL
and	NULL
d	NULL
)	NULL
.	NULL

We	NULL
observe	NULL
constitutive	NULL
expression	NULL
of	NULL
IxBa	NULL
mRNA	NULL
(	NULL
28	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
c	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
this	NULL
expression	NULL
is	NULL
further	NULL
stimulated	NULL
by	NULL
PMA	NULL
and	NULL
PMA/Iono	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
c	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
.	NULL

PG490	NULL
potently	NULL
inhibits	NULL
IxBa	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
c	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
7-9	NULL
)	NULL
,	NULL
whereas	NULL
1,000	NULL
ng/ml	NULL
CsA	NULL
shows	NULL
only	NULL
limited	NULL
inhibition	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
c	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mRNA	NULL
expression	NULL
for	NULL
NF90	NULL
,	NULL
a	NULL
transcriptional	NULL
regulator	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
13	NULL
)	NULL
,	NULL
is	NULL
significantly	NULL
induced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
200	NULL
and	NULL
1,000	NULL
ng/ml	NULL
PG490	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
d	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
versus	NULL
lane	NULL
2	NULL
and	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
versus	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
GAPDH	NULL
mRNA	NULL
are	NULL
unaltered	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
and	NULL
drug	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
e	NULL
)	NULL
.	NULL

Our	NULL
observations	NULL
that	NULL
PGA490	NULL
causes	NULL
more	NULL
complete	NULL
inhibition	NULL
of	NULL
IL-2	NULL
expression	NULL
than	NULL
CsA	NULL
and	NULL
that	NULL
PG490	NULL
but	NULL
not	NULL
CsA	NULL
inhibits	NULL
IxBa	NULL
mRNA	NULL
expression	NULL
and	NULL
enhances	NULL
NF90	NULL
mRNA	NULL
expression	NULL
establish	NULL
that	NULL
PGA490	NULL
modulates	NULL
gene	NULL
expression	NULL
through	NULL
distinctly	NULL
different	NULL
mechanisms	NULL
than	NULL
CsA	NULL
.	NULL

PG490	NULL
Inhibits	NULL
IL-2	NULL
Gene	NULL
Transcription	NULL
through	NULL
Mechanisms	NULL
Different	NULL
Than	NULL
CsA-We	NULL
next	NULL
demonstrated	NULL
that	NULL
PG490	NULL
inhibits	NULL
activation	NULL
of	NULL
an	NULL
IL-2	NULL
luciferase	NULL
reporter	NULL
gene	NULL
transfected	NULL
transiently	NULL
and	NULL
stably	NULL
into	NULL
Jurkat	NULL
T-cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
and	NULL
this	NULL
result	NULL
implies	NULL
that	NULL
PG490	NULL
inhibits	NULL
IL-2	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

We	NULL
used	NULL
the	NULL
IL-2	NULL
luciferase	NULL
assay	NULL
to	NULL
test	NULL
the	NULL
ability	NULL
of	NULL
PGA490	NULL
to	NULL
inhibit	NULL
the	NULL
CsA-resistant	NULL
pathway	NULL
of	NULL
T-cell	NULL
activation	NULL
achieved	NULL
by	NULL
stimulation	NULL
with	NULL
PMA	NULL
in	NULL
combination	NULL
with	NULL
anti-CD28	NULL
monoclonal	NULL
antibody	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
stimulated	NULL
Jurkat	NULL
T-cells	NULL
that	NULL
stably	NULL
express	NULL
the	NULL
IL-2	NULL
luciferase	NULL
reporter	NULL
gene	NULL
with	NULL
either	NULL
PMA	NULL
+	NULL
anti-CD28	NULL
antibody	NULL
(	NULL
PMA/aCD28	NULL
)	NULL
,	NULL
or	NULL
with	NULL
PMA/	NULL
Tono	NULL
,	NULL
each	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PG490	NULL
or	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

For	NULL
T-cells	NULL
stimulated	NULL
with	NULL
PMA/Iono	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
,	NULL
the	NULL
IC	NULL
;	NULL
,	NULL
is	NULL
approximately	NULL
20	NULL
ng/ml	NULL
(	NULL
56	NULL
nx	NULL
)	NULL
for	NULL
PG490	NULL
and	NULL
approximately	NULL
3	NULL
ng/ml	NULL
(	NULL
2.5	NULL
nx	NULL
)	NULL
for	NULL
CsA	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
for	NULL
T-cells	NULL
stimulated	NULL
with	NULL
PMA/aCD28	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
,	NULL
the	NULL
IC	NULL
;	NULL
,	NULL
is	NULL
approximately	NULL
50	NULL
ng/ml	NULL
for	NULL
PG490	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
,	NULL
and	NULL
CsA	NULL
is	NULL
completely	NULL
ineffective	NULL
in	NULL
inhibiting	NULL
this	NULL
pathway	NULL
of	NULL
stimulation	NULL
.	NULL

At	NULL
the	NULL
two	NULL
lower	NULL
doses	NULL
of	NULL
PG490	NULL
but	NULL
not	NULL
of	NULL
CsA	NULL
,	NULL
we	NULL
observed	NULL
modest	NULL
increases	NULL
in	NULL
IL-2	NULL
luciferase	NULL
activity	NULL
before	NULL
inhibition	NULL
occurs	NULL
at	NULL
the	NULL
higher	NULL
doses	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
although	NULL
CsA	NULL
is	NULL
more	NULL
potent	NULL
than	NULL
PG490	NULL
in	NULL
inhibiting	NULL
PMA/Iono-stimulated	NULL
IL-2	NULL
luciferase	NULL
activity	NULL
,	NULL
PG490	NULL
is	NULL
capable	NULL
of	NULL
inhibiting	NULL
T-cell	NULL
activation	NULL
triggered	NULL
through	NULL
a	NULL
costimulatory	NULL
receptor	NULL
,	NULL
a	NULL
situation	NULL
in	NULL
which	NULL
CsA	NULL
is	NULL
ineffective	NULL
.	NULL

To	NULL
explore	NULL
further	NULL
the	NULL
mechanistic	NULL
differences	NULL
between	NULL
PG490	NULL
and	NULL
CsA	NULL
and	NULL
FK506	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effects	NULL
of	NULL
calcineurin	NULL
overexpression	NULL
on	NULL
sensitivity	NULL
to	NULL
inhibition	NULL
by	NULL
these	NULL
immunosuppressant	NULL
drugs	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
Overexpression	NULL
of	NULL
calcineurin	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
confers	NULL
relative	NULL
resistance	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
CsA	NULL
and	NULL
FK506	NULL
upon	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

We	NULL
transiently	NULL
cotransfected	NULL
Jurkat	NULL
T-cells	NULL
with	NULL
the	NULL
IL-2	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
together	NULL
with	NULL
either	NULL
an	NULL
empty	NULL
expression	NULL
vector	NULL
or	NULL
with	NULL
expression	NULL
vectors	NULL
encoding	NULL
calcineurin	NULL
A	NULL
and	NULL
B	NULL
subunits	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
transfected	NULL
T-cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA/	NULL
Tono	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
doses	NULL
of	NULL
PG490	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
leff	NULL
panel	NULL
)	NULL
,	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
center	NULL
panel	NULL
)	NULL
,	NULL
or	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

There	NULL
is	NULL
no	NULL
shift	NULL
in	NULL
the	NULL
dose-inhibition	NULL
curve	NULL
of	NULL
IL-2	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
€	NULL
soo	NULL
S	NULL
P	NULL
+I	NULL
P+aCD28	NULL
.	NULL

;	NULL
5	NULL
T	NULL
,	NULL
<	NULL
to	NULL
2004	NULL
in	NULL
/	NULL
\	NULL
A	NULL
5	NULL
§1oo	NULL
--	NULL
-	NULL
``	NULL
``	NULL
I	NULL
|=	NULL
=	NULL
i	NULL
IT	NULL
_	NULL
]	NULL
o	NULL
4	NULL
e	NULL
``	NULL
a	NULL
1	NULL
I	NULL
it	NULL
I	NULL
T	NULL
T	NULL
3	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
PG490	NULL
(	NULL
ng/ml	NULL
)	NULL
-a-CsA	NULL
(	NULL
ng/ml	NULL
)	NULL
--	NULL
-	NULL
t	NULL
r	NULL
T	NULL
7	NULL
t	NULL
T	NULL
0.01	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
0.001	NULL
0.01	NULL
0.1	NULL
1	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
~PG490	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

CsA	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

FK506	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

pEF	NULL
-o-	NULL
u	NULL
IL-2	NULL
Luciferase	NULL
Activity	NULL
pEF	NULL
CNA	NULL
+	NULL
pEF	NULL
CNB	NULL
==	NULL
--	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

PG490	NULL
inhibits	NULL
IL-2	NULL
transcriptional	NULL
activation	NULL
through	NULL
mechanisms	NULL
different	NULL
from	NULL
CsA	NULL
.	NULL

A	NULL
,	NULL
PG490	NULL
but	NULL
not	NULL
CsA	NULL
inhibits	NULL
T-cell	NULL
activation	NULL
stimulated	NULL
through	NULL
costimulatory	NULL
receptor	NULL
CD28	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
that	NULL
stably	NULL
express	NULL
an	NULL
IL-2	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
were	NULL
stimulated	NULL
for	NULL
15	NULL
h	NULL
with	NULL
either	NULL
P/I	NULL
or	NULL
P+a	NULL
@	NULL
CD28	NULL
monoclonal	NULL
antibody	NULL
(	NULL
YTH913.12	NULL
,	NULL
BIOSOURCE	NULL
)	NULL
then	NULL
whole	NULL
cell	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
mean	NULL
luciferase	NULL
activity	NULL
in	NULL
nonstimulated	NULL
cells	NULL
was	NULL
~2,000	NULL
RLU	NULL
,	NULL
in	NULL
P/I-stimulated	NULL
cells	NULL
was	NULL
~76,000	NULL
RLU	NULL
,	NULL
and	NULL
in	NULL
cells	NULL
was	NULL
~8,400	NULL
RLU	NULL
.	NULL

For	NULL
each	NULL
independent	NULL
experiment	NULL
,	NULL
the	NULL
P/I-stimulated	NULL
and	NULL
the	NULL
P/aCD28-stimu-lated	NULL
luciferase	NULL
values	NULL
with	NULL
zero	NULL
drug	NULL
present	NULL
were	NULL
set	NULL
as	NULL
100	NULL
%	NULL
(	NULL
these	NULL
values	NULL
are	NULL
not	NULL
plotted	NULL
because	NULL
the	NULL
x	NULL
axis	NULL
is	NULL
on	NULL
a	NULL
log	NULL
scale	NULL
)	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

B	NULL
,	NULL
PG490	NULL
inhibition	NULL
of	NULL
T-cell	NULL
activation	NULL
is	NULL
unaffected	NULL
by	NULL
overexpression	NULL
of	NULL
calcineurin	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
an	NULL
IL-2	NULL
luciferase	NULL
reporter	NULL
construct	NULL
,	NULL
together	NULL
with	NULL
either	NULL
empty	NULL
expression	NULL
vector	NULL
(	NULL
filled	NULL
squares	NULL
)	NULL
,	NULL
or	NULL
with	NULL
expression	NULL
vectors	NULL
directing	NULL
synthesis	NULL
of	NULL
calcineurin	NULL
A	NULL
and	NULL
calcineurin	NULL
B	NULL
(	NULL
empty	NULL
squares	NULL
)	NULL
.	NULL

20	NULL
h	NULL
following	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
P/I	NULL
for	NULL
6	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PG490	NULL
,	NULL
CsA	NULL
,	NULL
or	NULL
FK506	NULL
at	NULL
the	NULL
indicated	NULL
doses	NULL
then	NULL
whole	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
for	NULL
analysis	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
mean	NULL
luciferase	NULL
activity	NULL
for	NULL
the	NULL
nonstimulated	NULL
condition	NULL
was	NULL
300	NULL
RLU	NULL
and	NULL
for	NULL
the	NULL
P/I-stimulated	NULL
condition	NULL
was	NULL
~800,000	NULL
RLU	NULL
.	NULL

For	NULL
each	NULL
experiment	NULL
,	NULL
the	NULL
P/I-stimulated	NULL
value	NULL
with	NULL
zero	NULL
drug	NULL
present	NULL
was	NULL
set	NULL
at	NULL
100	NULL
%	NULL
(	NULL
this	NULL
point	NULL
is	NULL
not	NULL
plotted	NULL
because	NULL
the	NULL
x	NULL
axis	NULL
is	NULL
on	NULL
a	NULL
log	NULL
scale	NULL
)	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Statistically	NULL
significant	NULL
differences	NULL
in	NULL
IL-2	NULL
transcription	NULL
at	NULL
the	NULL
same	NULL
doses	NULL
of	NULL
CsA	NULL
or	NULL
FK506	NULL
following	NULL
transfection	NULL
of	NULL
calcineurin	NULL
expression	NULL
plasmids	NULL
are	NULL
indicated	NULL
(	NULL
*p	NULL
<	NULL
0.05	NULL
;	NULL
**p	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

transcription	NULL
by	NULL
PG490	NULL
conferred	NULL
by	NULL
overexpression	NULL
of	NULL
calcineurin	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
overexpression	NULL
of	NULL
calcineurin	NULL
shifts	NULL
the	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
CsA	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
from	NULL
approximately	NULL
2	NULL
to	NULL
10	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
center	NULL
panel	NULL
)	NULL
,	NULL
and	NULL
shifts	NULL
the	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
FK506	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
from	NULL
approximately	NULL
0.2	NULL
to	NULL
1	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
PG490	NULL
inhibits	NULL
IL-2	NULL
transcription	NULL
through	NULL
mechanisms	NULL
distinct	NULL
from	NULL
CsA	NULL
and	NULL
FK506	NULL
,	NULL
and	NULL
which	NULL
probably	NULL
do	NULL
not	NULL
involve	NULL
calcineurin	NULL
.	NULL

PG490	NULL
Inhibits	NULL
Transcriptional	NULL
Activation	NULL
and	NULL
Also	NULL
DNA	NULL
Binding	NULL
of	NULL
the	NULL
Regulator	NULL
of	NULL
the	NULL
Purine-box/	NULL
ARRE/NF-AT	NULL
Target	NULL
Site	NULL
in	NULL
the	NULL
IL-2	NULL
Enhancer-After	NULL
demonstrating	NULL
that	NULL
PG490	NULL
inhibits	NULL
IL-2	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
,	NULL
we	NULL
next	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
PG490	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
and	NULL
transcriptional	NULL
activation	NULL
of	NULL
specific	NULL
factors	NULL
controlling	NULL
the	NULL
purine-box/ARRE/NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
sequences	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

11	NULL
)	NULL
.	NULL

We	NULL
used	NULL
EMSA	NULL
to	NULL
analyze	NULL
the	NULL
effects	NULL
of	NULL
PG490	NULL
on	NULL
the	NULL
PMA/Iono-induced	NULL
Jurkat	NULL
T-cell	NULL
purine-box/ARRE/NF-AT	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

PG490	NULL
inhibits	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
purine-box/	NULL
ARRE-EMSA	NULL
complex	NULL
with	NULL
an	NULL
IC	NULL
;	NULL
,	NULL
slightly	NULL
below	NULL
200	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

At	NULL
1,000	NULL
ng/ml	NULL
PG490	NULL
,	NULL
the	NULL
PMA/Iono-induced	NULL
purine-box/ARRE-EMSA	NULL
complex	NULL
is	NULL
unde-	NULL
PG490	NULL
Inhibits	NULL
Purine-box	NULL
/	NULL
NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Transcription	NULL
A	NULL
EMSA	NULL
Pu-box/	NULL
NFE-AT	NULL
*	NULL
!	NULL
'	NULL

''	NULL
N	NULL
I	NULL
5	NULL
PM/PG490	NULL
1000	NULL
6	NULL
PM/CsA	NULL
1000	NULL
4	NULL
PMPG490	NULL
200	NULL
a	NULL
a	NULL
<	NULL
G	NULL
=	NULL
&	NULL
Pu-box/NF-AT	NULL
Luciferase	NULL
Activity	NULL
(	NULL
fold	NULL
activation	NULL
)	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

PG490	NULL
inhibits	NULL
purine-box/NF-AT	NULL
transcriptional	NULL
activation	NULL
and	NULL
induced	NULL
purine-box/ARRE/NF-AT	NULL
DNA	NULL
binding	NULL
.	NULL

A	NULL
,	NULL
EMSA	NULL
analysis	NULL
showing	NULL
inhibition	NULL
of	NULL
induced	NULL
purine-box/ARRE/NF-AT	NULL
DNA	NULL
binding	NULL
activity	NULL
by	NULL
PG490	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
were	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
P/I	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
PG490	NULL
then	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
DNA	NULL
binding	NULL
activities	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
.	NULL

B	NULL
,	NULL
inhibition	NULL
of	NULL
purine-box/NF-AT	NULL
transcriptional	NULL
activation	NULL
by	NULL
PG490	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
that	NULL
stably	NULL
express	NULL
a	NULL
purine-box/	NULL
NF-AT	NULL
luciferase	NULL
reporter	NULL
construct	NULL
were	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
P/I	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
doses	NULL
of	NULL
PG490	NULL
.	NULL

The	NULL
mean	NULL
luciferase	NULL
activity	NULL
in	NULL
nonstimulated	NULL
cells	NULL
was	NULL
550	NULL
RLU	NULL
and	NULL
in	NULL
P/I-stimulated	NULL
cells	NULL
was	NULL
~1,100,000	NULL
RLU	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Statistically	NULL
significant	NULL
inhibitions	NULL
compared	NULL
with	NULL
no	NULL
drug	NULL
treatment	NULL
are	NULL
indicated	NULL
(	NULL
*p	NULL
<	NULL
0.05	NULL
;	NULL
**p	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

Pu	NULL
,	NULL
purine	NULL
.	NULL

tectable	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
is	NULL
therefore	NULL
weaker	NULL
than	NULL
the	NULL
EMSA	NULL
complex	NULL
constitutively	NULL
present	NULL
in	NULL
nonstimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
weaker	NULL
than	NULL
the	NULL
complex	NULL
induced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,000	NULL
ng/ml	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

PG490	NULL
is	NULL
more	NULL
potent	NULL
in	NULL
inhibiting	NULL
PMA/Iono-stimulated	NULL
transcriptional	NULL
activation	NULL
of	NULL
a	NULL
purine-box/NF-AT	NULL
luciferase	NULL
reporter	NULL
gene	NULL
with	NULL
an	NULL
IC	NULL
;	NULL
,	NULL
of	NULL
approximately	NULL
20	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
3	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
demonstrate	NULL
that	NULL
PG490	NULL
inhibits	NULL
both	NULL
transcriptional	NULL
activation	NULL
and	NULL
also	NULL
DNA	NULL
binding	NULL
of	NULL
the	NULL
regulator	NULL
operating	NULL
at	NULL
the	NULL
purine-box/ARRE/NF-AT	NULL
target	NULL
sequence	NULL
and	NULL
that	NULL
the	NULL
predominant	NULL
site	NULL
of	NULL
signaling	NULL
inhibition	NULL
is	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
after	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

PG490	NULL
Inhibits	NULL
Transcriptional	NULL
Activation	NULL
and	NULL
not	NULL
DNA	NULL
Binding	NULL
of	NULL
NF-	NULL
«	NULL
B-We	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
PG490	NULL
on	NULL
NF-kB	NULL
signaling	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

We	NULL
show	NULL
constitutive	NULL
expression	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
anchoring	NULL
protein	NULL
,	NULL
I	NULL
«	NULL
Ba	NULL
,	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
nonstimulated	NULL
Jurkat	NULL
T-cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
IxBa	NULL
expression	NULL
decreases	NULL
following	NULL
stimulation	NULL
with	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
2	NULL
versus	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

PG490	NULL
at	NULL
200	NULL
and	NULL
1,000	NULL
ng/ml	NULL
causes	NULL
nearly	NULL
complete	NULL
inhibition	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
protein	NULL
expression	NULL
in	NULL
PMA-stimulated	NULL
T-cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
and	NULL
this	NULL
result	NULL
correlates	NULL
with	NULL
PG490	NULL
inhibition	NULL
of	NULL
I	NULL
«	NULL
xBae	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
panel	NULL
c	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

At	NULL
the	NULL
level	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
,	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
T-cells	NULL
with	NULL
PMA	NULL
induces	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
new	NULL
band	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
,	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
2-6	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
subunit	NULL
within	NULL
this	NULL
complex	NULL
is	NULL
established	NULL
by	NULL
the	NULL
quantitative	NULL
supershift	NULL
of	NULL
the	NULL
inducible	NULL
complex	NULL
with	NULL
an	NULL
antibody	NULL
to	NULL
p65	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
7-12	NULL
)	NULL
.	NULL

PG490	NULL
at	NULL
20	NULL
ng/ml	NULL
causes	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
NF-	NULL
«	NULL
B-EMSA	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
3	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
and	NULL
PG490	NULL
at	NULL
200	NULL
and	NULL
1,000	NULL
ng/ml	NULL
causes	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
the	NULL
strength	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
versus	NULL
lanes	NULL
2	NULL
and	NULL
10	NULL
,	NULL
lane	NULL
11	NULL
versus	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
PG490	NULL
Inhibits	NULL
Purine-box	NULL
/	NULL
NF-AT	NULL
and	NULL
NF-kB	NULL
Transcription	NULL
13447	NULL
«	NULL
p65	NULL
A	NULL
Immunoblot	NULL
D	NULL
EMSA	NULL
IkBa	NULL
=	NULL
--	NULL
bub	NULL
#	NULL
i+	NULL
-	NULL
NF-	NULL
<	NULL
B*	NULL
“	NULL
E55	NULL
|	NULL
BEMSA	NULL
NExr	NULL
``	NULL
ﬂu	NULL
“	NULL
“	NULL
uu	NULL
'	NULL
boul	NULL
bout	NULL
tl	NULL
bul	NULL
+	NULL
NF-cB*	NULL
o	NULL
i	NULL
esl	NULL
Icl	NULL
|	NULL
bb	NULL
H4	NULL
sgig	NULL
illi	NULL
M	NULL
‘	NULL
H	NULL
“	NULL
H	NULL
“	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

§	NULL
$	NULL
$	NULL
E	NULL
$	NULL
§	NULL
§	NULL
s	NULL
N	NULL
``	NULL
cg	NULL
g	NULL
g	NULL
8	NULL
6	NULL
6	NULL
%	NULL
4	NULL
4	NULL
£	NULL
|	NULL
a	NULL
>	NULL
gggnumgﬁggég	NULL
Q8	NULL
08	NULL
3—-	NULL
f—Nﬂﬂ	NULL
‘	NULL
m	NULL
‘	NULL
ﬂhwmgzvﬂv	NULL
§§	NULL
93	NULL
0	NULL
a	NULL
§°3	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
Plc	NULL
C	NULL
(	NULL
ng	NULL
'm	NULL
!	NULL
)	NULL

a	NULL
a	NULL
®	NULL
T	NULL
&	NULL
&	NULL
&	NULL
-	NULL
g	NULL
>	NULL
9	NULL
9	NULL
9	NULL
a	NULL
7	NULL
9	NULL
t	NULL
<	NULL
Cie	NULL
fffl..fEf	NULL
!	NULL

|	NULL
f	NULL
``	NULL
“	NULL
g	NULL
gaunna	NULL
%	NULL
nn	NULL
%	NULL
na	NULL
3g	NULL
&	NULL
-	NULL
m	NULL
#	NULL
in	NULL
o	NULL
m	NULL
o	NULL
o	NULL
a	NULL
:	NULL
bl	NULL
mez	NULL
&	NULL
¢t	NULL
Pr	NULL
®	NULL
2-0	NULL
o	NULL
U	NULL
§§	NULL
lid	NULL
F2	NULL
ins	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

J	NULL
£10	NULL
|	NULL
2	NULL
TNF-	NULL
0900	NULL
_	NULL
oy	NULL
8	NULL
8	NULL
20-	NULL
3	NULL
TNEPc	NULL
4	NULL
e	NULL
+	NULL
>	NULL
as	NULL
-	NULL
4	NULL
TNF/PG4SO	NULL
20	NULL
/	NULL
++	NULL
'	NULL
l	NULL
5	NULL
TNF/PGA490	NULL
200	NULL
|	NULL
|+*	NULL
&	NULL
o	NULL
0	NULL
6	NULL
TNF/PG490	NULL
1000	NULL
|+*	NULL
_______________	NULL
0	NULL
2	NULL
4	NULL
NF-kB	NULL
Luciferase	NULL
Activity	NULL
(	NULL
fold	NULL
activation	NULL
)	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

PG490	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
with	NULL
no	NULL
inhibition	NULL
of	NULL
induced	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
.	NULL

A	NULL
,	NULL
Western	NULL
immunoblot	NULL
of	NULL
cytoplasmic	NULL
IxBa	NULL
expression	NULL
following	NULL
PMA	NULL
stimulation	NULL
and	NULL
effects	NULL
of	NULL
PG490	NULL
.	NULL

B	NULL
,	NULL
EMSA	NULL
analysis	NULL
of	NULL
nuclear	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
following	NULL
PMA	NULL
stimulation	NULL
and	NULL
effects	NULL
of	NULL
PG490	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
for	NULL
3	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
PG490	NULL
or	NULL
CsA	NULL
and	NULL
then	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
used	NULL
for	NULL
Western	NULL
and	NULL
EMSA	NULL
analyses	NULL
.	NULL

Supershift	NULL
analyses	NULL
were	NULL
performed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
2	NULL
pl	NULL
of	NULL
IgG	NULL
against	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
(	NULL
sc-109	NULL
,	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

C	NULL
,	NULL
inhibition	NULL
of	NULL
PMA-stimulated	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
by	NULL
PG490	NULL
.	NULL

The	NULL
mean	NULL
luciferase	NULL
activity	NULL
per	NULL
20	NULL
ug	NULL
of	NULL
protein	NULL
in	NULL
NS	NULL
cells	NULL
was	NULL
34,500	NULL
RLU	NULL
and	NULL
~1,820,000	NULL
RLU	NULL
in	NULL
PMA-stimulated	NULL
cells	NULL
.	NULL

D	NULL
,	NULL
EMSA	NULL
analysis	NULL
of	NULL
nuclear	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
following	NULL
P/I	NULL
stimulation	NULL
and	NULL
effects	NULL
of	NULL
PG490	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
analyzed	NULL
are	NULL
the	NULL
same	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
and	NULL
were	NULL
prepared	NULL
from	NULL
Jurkat	NULL
T-cells	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
PMA/Iono	NULL
.	NULL

E	NULL
,	NULL
inhibition	NULL
of	NULL
PMA/Iono-stimulated	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
by	NULL
PG490	NULL
.	NULL

The	NULL
mean	NULL
luciferase	NULL
activity	NULL
per	NULL
20	NULL
ug	NULL
of	NULL
protein	NULL
in	NULL
NS	NULL
cells	NULL
was	NULL
60,595	NULL
RLU	NULL
and	NULL
~2,489,652	NULL
RLU	NULL
in	NULL
PMA/Iono-stimulated	NULL
cells	NULL
.	NULL

F	NULL
,	NULL
inhibition	NULL
of	NULL
TNF-a-stimulated	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
by	NULL
PG490	NULL
.	NULL

The	NULL
mean	NULL
luciferase	NULL
activity	NULL
per	NULL
20	NULL
ug	NULL
of	NULL
protein	NULL
in	NULL
NS	NULL
cells	NULL
was	NULL
82,147	NULL
RLU	NULL
and	NULL
~851,202	NULL
RLU	NULL
in	NULL
TNF-o-stimulated	NULL
cells	NULL
.	NULL

For	NULL
the	NULL
NF-	NULL
«	NULL
B-luciferase	NULL
experiments	NULL
in	NULL
C	NULL
,	NULL
£	NULL
,	NULL
and	NULL
F	NULL
,	NULL
Jurkat	NULL
T-cells	NULL
that	NULL
stably	NULL
express	NULL
an	NULL
NF-xB	NULL
luciferase	NULL
reporter	NULL
construct	NULL
were	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
either	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
,	NULL
P/I	NULL
(	NULL
2	NULL
uM	NULL
)	NULL
,	NULL
or	NULL
TNF-a	NULL
«	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
doses	NULL
of	NULL
PGA490	NULL
or	NULL
CsA	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Statistically	NULL
significant	NULL
inhibitions	NULL
compared	NULL
with	NULL
no	NULL
drug	NULL
treatment	NULL
are	NULL
indicated	NULL
(	NULL
*p	NULL
<	NULL
0.05	NULL
;	NULL
**p	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

which	NULL
we	NULL
observe	NULL
at	NULL
200	NULL
and	NULL
1,000	NULL
ng/ml	NULL
PG490	NULL
occurs	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
PG490	NULL
inhibition	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
expression	NULL
,	NULL
which	NULL
likely	NULL
allows	NULL
increased	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
.	NULL

Despite	NULL
the	NULL
development	NULL
of	NULL
a	NULL
strong	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
complex	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
T-cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
200	NULL
ng/ml	NULL
PG490	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
we	NULL
observe	NULL
nearly	NULL
90	NULL
%	NULL
inhibition	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

CsA	NULL
at	NULL
1,000	NULL
ng/ml	NULL
shows	NULL
no	NULL
significant	NULL
inhibition	NULL
of	NULL
PMA-stimulated	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
which	NULL
is	NULL
expected	NULL
,	NULL
because	NULL
CsA	NULL
acts	NULL
predominantly	NULL
to	NULL
inhibit	NULL
calcium-mediated	NULL
activation	NULL
path-ways	NULL
.	NULL

The	NULL
inhibitory	NULL
effects	NULL
of	NULL
PG490	NULL
on	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcriptional	NULL
activation	NULL
were	NULL
identical	NULL
using	NULL
stably	NULL
or	NULL
transiently	NULL
transfected	NULL
cells	NULL
,	NULL
or	NULL
when	NULL
using	NULL
a	NULL
consensus	NULL
immunoglobulin	NULL
k	NULL
light	NULL
chain	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
monomer	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
minimal	NULL
IL-8	NULL
promoter	NULL
,	NULL
or	NULL
the	NULL
IL-2	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
trimer	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
PMA	NULL
stimulation	NULL
alone	NULL
activates	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
and	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
,	NULL
substantial	NULL
expression	NULL
of	NULL
IL-2	NULL
mRNA	NULL
and	NULL
protein	NULL
requires	NULL
the	NULL
additional	NULL
calcium	NULL
mobilization	NULL
achieved	NULL
following	NULL
ligation	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
or	NULL
with	NULL
ionophore	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
also	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
PG490	NULL
upon	NULL
NF-	NULL
«	NULL
B	NULL
signaling	NULL
triggered	NULL
with	NULL
PMA	NULL
+	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
D	NULL
and	NULL
£	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
results	NULL
observed	NULL
with	NULL
PMA	NULL
stimulation	NULL
,	NULL
PMA/Iono	NULL
stimulation	NULL
causes	NULL
the	NULL
induction	NULL
of	NULL
specific	NULL
nuclear	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
,	NULL
which	NULL
increases	NULL
when	NULL
cells	NULL
are	NULL
stimulated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PGA490	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
,	NULL
lanes	NULL
3-5	NULL
and	NULL
9-11	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
a	NULL
specific	NULL
antibody	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
causes	NULL
a	NULL
quantitative	NULL
supershift	NULL
of	NULL
the	NULL
inducible	NULL
DNA	NULL
binding	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
,	NULL
lanes	NULL
7-12	NULL
)	NULL
.	NULL

Cells	NULL
stimulated	NULL
with	NULL
PMA/Iono	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
show	NULL
much	NULL
less	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
than	NULL
cells	NULL
stimulated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PG490	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
,	NULL
lane	NULL
6	NULL
versus	NULL
lanes	NULL
3-5	NULL
)	NULL
,	NULL
underscoring	NULL
the	NULL
different	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
these	NULL
immunosuppressant	NULL
drugs	NULL
.	NULL

Despite	NULL
the	NULL
development	NULL
of	NULL
strong	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
PG490	NULL
causes	NULL
near	NULL
complete	NULL
inhibition	NULL
of	NULL
PMA/Iono-stimulated	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
with	NULL
an	NULL
IC	NULL
;	NULL
,	NULL
of	NULL
approximately	NULL
50	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

46	NULL
,	NULL
lanes	NULL
3-5	NULL
)	NULL
.	NULL

Transcriptional	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
stimulated	NULL
by	NULL
TNF-a	NULL
is	NULL
also	NULL
inhibited	NULL
by	NULL
PG490	NULL
,	NULL
with	NULL
an	NULL
IC	NULL
;	NULL
,	NULL
of	NULL
approximately	NULL
50	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

4F	NULL
,	NULL
rows	NULL
3-6	NULL
)	NULL
.	NULL

PG490	NULL
nearly	NULL
completely	NULL
inhibits	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
triggered	NULL
by	NULL
all	NULL
stimuli	NULL
tested	NULL
(	NULL
PMA	NULL
,	NULL
PMA/Iono	NULL
,	NULL
TNF	NULL
-a	NULL
«	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
demonstrate	NULL
that	NULL
PG490	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
at	NULL
a	NULL
step	NULL
after	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

PG490	NULL
Inhibits	NULL
Activation	NULL
through	NULL
NF-	NULL
«	NULL
kB	NULL
Transactivation	NULL
Domains	NULL
TA1l	NULL
and	NULL
TA2-Because	NULL
PG490	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
without	NULL
inhibiting	NULL
nuclear	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
B-E	NULL
)	NULL
,	NULL
we	NULL
next	NULL
investigated	NULL
whether	NULL
PG490	NULL
can	NULL
inhibit	NULL
transcriptional	NULL
activation	NULL
through	NULL
a	NULL
chimeric	NULL
transcription	NULL
factor	NULL
in	NULL
which	NULL
the	NULL
transactivating	NULL
domain	NULL
of	NULL
p65	NULL
is	NULL
fused	NULL
to	NULL
the	NULL
yeast	NULL
GAL4	NULL
DNA	NULL
binding	NULL
domain	NULL
.	NULL

Schmitz	NULL
and	NULL
Baeuerle	NULL
(	NULL
25	NULL
)	NULL
identified	NULL
that	NULL
the	NULL
C-terminal	NULL
portion	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
contains	NULL
two	NULL
transactivation	NULL
domains	NULL
,	NULL
TAl	NULL
and	NULL
TAZ	NULL
,	NULL
and	NULL
showed	NULL
that	NULL
chimeric	NULL
fusion	NULL
proteins	NULL
with	NULL
the	NULL
TAl	NULL
(	NULL
p65	NULL
amino	NULL
acids	NULL
522-551	NULL
)	NULL
or	NULL
TAl	NULL
+	NULL
TAZ	NULL
(	NULL
p65	NULL
amino	NULL
acids	NULL
286-521	NULL
)	NULL
domains	NULL
fused	NULL
to	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
GAL4	NULL
(	NULL
amino	NULL
acids	NULL
1-147	NULL
)	NULL
confer	NULL
PMA-inducible	NULL
transcriptional	NULL
activation	NULL
onto	NULL
a	NULL
GAL4	NULL
reporter	NULL
gene	NULL
(	NULL
25	NULL
,	NULL
31	NULL
)	NULL
.	NULL

We	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
T-cells	NULL
with	NULL
a	NULL
GAL4	NULL
response	NULL
element-lu-ciferase	NULL
reporter	NULL
construct	NULL
,	NULL
together	NULL
with	NULL
expression	NULL
constructs	NULL
encoding	NULL
either	NULL
the	NULL
GAL4	NULL
DNA	NULL
binding	NULL
domain	NULL
alone	NULL
(	NULL
GAL4DB	NULL
)	NULL
,	NULL
GAL4DB-p65TA1I	NULL
,	NULL
or	NULL
GAL4DB	NULL
p65	NULL
(	NULL
TAl+	NULL
TA2	NULL
)	NULL
.	NULL

After	NULL
recovery	NULL
from	NULL
the	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
doses	NULL
of	NULL
PG490	NULL
.	NULL

The	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
13448	NULL
{	NULL
ng/ml	NULL
)	NULL
20	NULL
--	NULL
#	NULL
P/PG4s0	NULL
200	NULL
-	NULL
%	NULL
PiPG430	NULL
1000	NULL
4	NULL
*	NULL
P/CsA	NULL
1000	NULL
I	NULL
--	NULL
a	NULL
GAL4	NULL
DB	NULL
p65	NULL
TAM	NULL
@	NULL
one	NULL
m	NULL
or	NULL
7	NULL
NS	NULL
8	NULL
P	NULL
9	NULL
P/PG430	NULL
20	NULL
10	NULL
P/PG420	NULL
200	NULL
11	NULL
P/PG420	NULL
1000	NULL
12	NULL
P/CsA	NULL
1000	NULL
GAL4	NULL
DB	NULL
p65	NULL
TA1+TA2	NULL
GAL4	NULL
RE	NULL
Luciferase	NULL
Activity	NULL
(	NULL
fold	NULL
activation	NULL
)	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

PG490	NULL
inhibits	NULL
activation	NULL
through	NULL
chimeric	NULL
transcription	NULL
factors	NULL
and	NULL
GAL4DB-NF-	NULL
«	NULL
B	NULL
{	NULL
TAl+TA2	NULL
}	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
GAL4RE	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
expression	NULL
plasmids	NULL
for	NULL
either	NULL
GAL4DB-p65	NULL
TAl	NULL
or	NULL
GAL4DB-p65	NULL
{	NULL
TA1+TA2	NULL
}	NULL
.	NULL

In	NULL
panel	NULL
a	NULL
,	NULL
cells	NULL
were	NULL
also	NULL
cotransfected	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
pEF	NULL
Renilla	NULL
luciferase	NULL
plasmid	NULL
to	NULL
normalize	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

20	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
PMA	NULL
then	NULL
whole	NULL
cells	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
(	NULL
panel	NULL
b	NULL
)	NULL
;	NULL
in	NULL
panel	NULL
a	NULL
,	NULL
both	NULL
firefly	NULL
and	NULL
Renilla	NULL
luciferase	NULL
were	NULL
assayed	NULL
using	NULL
a	NULL
dual	NULL
luciferase	NULL
assay	NULL
kit	NULL
(	NULL
Pro-mega	NULL
)	NULL
.	NULL

In	NULL
panel	NULL
a	NULL
,	NULL
the	NULL
mean	NULL
normalized	NULL
luciferase	NULL
activity	NULL
in	NULL
NS	NULL
cells	NULL
was	NULL
6,600	NULL
RLU	NULL
and	NULL
~9,600	NULL
RLU	NULL
in	NULL
PMA-stimulated	NULL
cells	NULL
;	NULL
in	NULL
panel	NULL
6	NULL
,	NULL
the	NULL
mean	NULL
luciferase	NULL
activity	NULL
per	NULL
20	NULL
ug	NULL
of	NULL
protein	NULL
in	NULL
NS	NULL
cells	NULL
was	NULL
258,000	NULL
RLU	NULL
and	NULL
~600,000	NULL
RLU	NULL
in	NULL
PMA-stimulated	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
represent	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

from	NULL
five	NULL
(	NULL
panel	NULL
a	NULL
)	NULL
and	NULL
three	NULL
(	NULL
panel	NULL
b	NULL
)	NULL
independent	NULL
experiments	NULL
.	NULL

Statistically	NULL
significant	NULL
inhibitions	NULL
of	NULL
the	NULL
PMA-stimulated	NULL
condition	NULL
by	NULL
PG490	NULL
are	NULL
indicated	NULL
(	NULL
*p	NULL
<	NULL
0.05	NULL
;	NULL
**	NULL
»	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

expression	NULL
construct	NULL
for	NULL
GAL4DB	NULL
alone	NULL
shows	NULL
no	NULL
transactivation	NULL
of	NULL
the	NULL
GAL4	NULL
response	NULL
element	NULL
(	NULL
GAL4RE	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
Jurkat	NULL
T-cells	NULL
contain	NULL
no	NULL
endogenous	NULL
acti-vators	NULL
of	NULL
the	NULL
GAL4RE	NULL
reporter	NULL
.	NULL

There	NULL
is	NULL
constitutive	NULL
transcription	NULL
by	NULL
the	NULL
chimeric	NULL
transcription	NULL
factor	NULL
,	NULL
GAL4DB-p65	NULL
TAL	NULL
,	NULL
and	NULL
this	NULL
transcription	NULL
is	NULL
enhanced	NULL
approximately	NULL
1.6-fold	NULL
following	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
and	NULL
the	NULL
PMA	NULL
enhancement	NULL
of	NULL
transcription	NULL
is	NULL
inhibited	NULL
by	NULL
PG49O	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
panel	NULL
a	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
a	NULL
greater	NULL
signal	NULL
with	NULL
a	NULL
similar	NULL
pattern	NULL
of	NULL
regulation	NULL
using	NULL
the	NULL
chimeric	NULL
transcription	NULL
factor	NULL
GAL4DB	NULL
p65	NULL
(	NULL
TAl	NULL
+	NULL
TA2	NULL
)	NULL
;	NULL
the	NULL
constitutive	NULL
transcription	NULL
is	NULL
enhanced	NULL
approximately	NULL
2.3-fold	NULL
following	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
and	NULL
the	NULL
PMA	NULL
enhancement	NULL
of	NULL
transcription	NULL
is	NULL
inhibited	NULL
by	NULL
PG490	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
panel	NULL
b	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
PG490	NULL
,	NULL
but	NULL
not	NULL
CsA	NULL
,	NULL
inhibits	NULL
transcription	NULL
through	NULL
the	NULL
C-terminal	NULL
transactivation	NULL
domains	NULL
TAl	NULL
and	NULL
TAl	NULL
+	NULL
TAZ	NULL
of	NULL
p65	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
panels	NULL
a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

The	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
PG490	NULL
inhibition	NULL
of	NULL
the	NULL
chimeric	NULL
transcription	NULL
factors	NULL
is	NULL
approximately	NULL
50	NULL
ng/ml	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
ICs	NULL
,	NULL
for	NULL
PG490	NULL
inhibition	NULL
of	NULL
endogenous	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
C	NULL
,	NULL
E	NULL
,	NULL
and	NULL
F	NULL
)	NULL
.	NULL

PG490	NULL
Inhibits	NULL
IL-8	NULL
Expression	NULL
in	NULL
16HBE	NULL
Human	NULL
Bronchial	NULL
Epithelial	NULL
Cells-NF-	NULL
«	NULL
B	NULL
is	NULL
important	NULL
for	NULL
transcriptional	NULL
activation	NULL
of	NULL
cytokine	NULL
genes	NULL
such	NULL
as	NULL
IL-8	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
including	NULL
epithelial	NULL
and	NULL
endothelial	NULL
cells	NULL
(	NULL
32	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
PG490	NULL
on	NULL
expression	NULL
of	NULL
IL-8	NULL
protein	NULL
and	NULL
mRNA	NULL
in	NULL
16HBE	NULL
transformed	NULL
human	NULL
bronchial	NULL
epithelial	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

PG490	NULL
at	NULL
20	NULL
ng/ml	NULL
inhibits	NULL
PMA-stimulated	NULL
IL-8	NULL
protein	NULL
and	NULL
mRNA	NULL
expression	NULL
more	NULL
effectively	NULL
than	NULL
CsA	NULL
at	NULL
1,000	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
panels	NULL
a	NULL
and	NULL
b	NULL
,	NULL
lane	NULL
3	NULL
versus	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
and	NULL
PG490	NULL
at	NULL
200	NULL
and	NULL
1,000	NULL
ng/ml	NULL
inhibits	NULL
PMA/Iono-stimulated	NULL
IL-8	NULL
expression	NULL
more	NULL
effectively	NULL
than	NULL
1,000	NULL
ng/ml	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
versus	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
PG490	NULL
inhibits	NULL
inflammatory	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
epithelial	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
mechanism	NULL
of	NULL
inhibition	NULL
is	NULL
distinctly	NULL
different	NULL
from	NULL
CsA	NULL
and	NULL
probably	NULL
involves	NULL
transcriptional	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

PG490	NULL
Inhibits	NULL
Purine-box	NULL
/	NULL
NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Transcription	NULL
10000	NULL
E	NULL
#	NULL
-	NULL
5000	NULL
a	NULL
7	NULL
%	NULL
6	NULL
8	NULL
a	NULL
[	NULL
=	NULL
s	NULL
e	NULL
§	NULL
§	NULL
o	NULL
sig	NULL
ingiml	NULL
g	NULL
g	NULL
£0	NULL
3	NULL
§	NULL
§	NULL
.	NULL

9	NULL
Y	NULL
<	NULL
4	NULL
0	NULL
0	NULL
0	NULL
a	NULL
€	NULL
€	NULL
$	NULL
2s	NULL
s	NULL
5	NULL
8	NULL
%	NULL
o.	NULL
o	NULL
.	NULL

A.	NULL
o.	NULL
E	NULL
E	NULL
o.	NULL
n.	NULL
C.	NULL
IL-8	NULL
.	NULL

'..*'.b	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

PG490	NULL
inhibits	NULL
bronchial	NULL
epithelial	NULL
cell	NULL
IL-8	NULL
expres-sion	NULL
.	NULL

16HBE	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
stimulants	NULL
and	NULL
immunomodulating	NULL
drugs	NULL
then	NULL
secreted	NULL
IL-8	NULL
was	NULL
analyzed	NULL
by	NULL
ELISA	NULL
(	NULL
Immunotech	NULL
)	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
was	NULL
prepared	NULL
and	NULL
analyzed	NULL
for	NULL
IL-8	NULL
and	NULL
GAPDH	NULL
mRNA	NULL
expression	NULL
by	NULL
Northern	NULL
hybridization	NULL
.	NULL

The	NULL
ELISA	NULL
data	NULL
are	NULL
the	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

from	NULL
four	NULL
independent	NULL
experiments	NULL
;	NULL
statistically	NULL
significant	NULL
inhibitions	NULL
by	NULL
PG490	NULL
or	NULL
CsA	NULL
are	NULL
indicated	NULL
(	NULL
*p	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

DISCUSSION	NULL
PG490	NULL
,	NULL
which	NULL
is	NULL
pure	NULL
triptolide	NULL
,	NULL
inhibits	NULL
T-cell	NULL
activation	NULL
and	NULL
early	NULL
cytokine	NULL
gene	NULL
transcription	NULL
in	NULL
T-cells	NULL
and	NULL
epithelial	NULL
cells	NULL
through	NULL
mechanisms	NULL
that	NULL
are	NULL
different	NULL
from	NULL
CsA	NULL
and	NULL
FK506	NULL
.	NULL

PG490	NULL
inhibits	NULL
transcriptional	NULL
activation	NULL
at	NULL
the	NULL
purine-box/ARRE/NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
sequences	NULL
after	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

In	NULL
previous	NULL
studies	NULL
of	NULL
the	NULL
T2	NULL
ethyl	NULL
acetate	NULL
extract	NULL
of	NULL
Tripterygium	NULL
,	NULL
Tao	NULL
et	NULL
al	NULL
.	NULL

(	NULL
9	NULL
)	NULL
inferred	NULL
that	NULL
the	NULL
immunosuppressive	NULL
properties	NULL
of	NULL
T2	NULL
are	NULL
due	NULL
to	NULL
triptolide	NULL
and	NULL
tripdiolide	NULL
and	NULL
showed	NULL
that	NULL
T2	NULL
completely	NULL
suppressed	NULL
mitogen-stimulated	NULL
IL-2	NULL
and	NULL
interferon-y	NULL
expression	NULL
in	NULL
T-cells	NULL
but	NULL
showed	NULL
only	NULL
limited	NULL
inhibition	NULL
of	NULL
IL-6	NULL
,	NULL
IL-2	NULL
receptor	NULL
,	NULL
and	NULL
transferrin	NULL
receptor	NULL
expression	NULL
(	NULL
10	NULL
)	NULL
.	NULL

IL-2	NULL
expression	NULL
was	NULL
inhibited	NULL
by	NULL
T2	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
,	NULL
as	NULL
revealed	NULL
by	NULL
an	NULL
IL-2	NULL
reporter	NULL
gene	NULL
assay	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
was	NULL
not	NULL
significantly	NULL
inhibited	NULL
by	NULL
immunosuppressive	NULL
doses	NULL
of	NULL
T2	NULL
,	NULL
triptolide	NULL
,	NULL
or	NULL
tripdiolide	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
our	NULL
experiments	NULL
,	NULL
we	NULL
studied	NULL
PG490	NULL
,	NULL
which	NULL
is	NULL
97	NULL
%	NULL
pure	NULL
triptolide	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
T2	NULL
ethyl	NULL
acetate	NULL
extract	NULL
that	NULL
contains	NULL
approximately	NULL
5	NULL
%	NULL
triptolide	NULL
.	NULL

We	NULL
found	NULL
that	NULL
PG490	NULL
potently	NULL
inhibits	NULL
IL-2	NULL
protein	NULL
and	NULL
mRNA	NULL
expression	NULL
,	NULL
and	NULL
this	NULL
inhibition	NULL
occurs	NULL
at	NULL
the	NULL
level	NULL
of	NULL
IL-2	NULL
transcription	NULL
,	NULL
and	NULL
our	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
characterization	NULL
of	NULL
T2	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Using	NULL
an	NULL
in	NULL
vivo	NULL
assay	NULL
,	NULL
we	NULL
found	NULL
that	NULL
overexpression	NULL
of	NULL
calcineurin	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
does	NULL
not	NULL
alter	NULL
sensitivity	NULL
to	NULL
inhibition	NULL
by	NULL
PG490	NULL
while	NULL
conferring	NULL
a	NULL
5-fold	NULL
relative	NULL
resistance	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
both	NULL
CsA	NULL
and	NULL
FK506	NULL
.	NULL

This	NULL
result	NULL
establishes	NULL
that	NULL
PG490	NULL
inhibits	NULL
IL-2	NULL
transcription	NULL
through	NULL
mechanisms	NULL
distinct	NULL
from	NULL
CsA	NULL
and	NULL
FK506	NULL
and	NULL
which	NULL
likely	NULL
do	NULL
not	NULL
involve	NULL
calcineurin	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
show	NULL
that	NULL
PG490	NULL
but	NULL
not	NULL
CsA	NULL
inhibits	NULL
IL-2	NULL
transcription	NULL
stimulated	NULL
by	NULL
PMA	NULL
and	NULL
monoclonal	NULL
antibody	NULL
YTH913.12	NULL
to	NULL
the	NULL
costimulatory	NULL
receptor	NULL
,	NULL
CD28	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
our	NULL
results	NULL
,	NULL
Tao	NULL
et	NULL
al	NULL
.	NULL

(	NULL
10	NULL
)	NULL
found	NULL
that	NULL
a	NULL
maximal	NULL
dose	NULL
of	NULL
T2	NULL
(	NULL
2	NULL
ug/ml	NULL
)	NULL
was	NULL
unable	NULL
to	NULL
inhibit	NULL
IL-2	NULL
secretion	NULL
by	NULL
purified	NULL
T-cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
+	NULL
monoclonal	NULL
antibody	NULL
9.3	NULL
to	NULL
CD28	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
this	NULL
difference	NULL
in	NULL
results	NULL
can	NULL
most	NULL
likely	NULL
be	NULL
attributed	NULL
to	NULL
our	NULL
use	NULL
of	NULL
pure	NULL
triptolide	NULL
compared	NULL
with	NULL
the	NULL
use	NULL
of	NULL
the	NULL
T2	NULL
mixture	NULL
(	NULL
10	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
only	NULL
a	NULL
fraction	NULL
of	NULL
triptolide	NULL
.	NULL

The	NULL
other	NULL
compounds	NULL
present	NULL
in	NULL
T2	NULL
may	NULL
be	NULL
physiologically	NULL
inactive	NULL
,	NULL
in	NULL
which	NULL
case	NULL
their	NULL
presence	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
PG490	NULL
Inhibits	NULL
Purine-box	NULL
/	NULL
NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Transcription	NULL
might	NULL
simply	NULL
limit	NULL
the	NULL
dose	NULL
availablity	NULL
of	NULL
triptolide	NULL
;	NULL
alterna-tively	NULL
,	NULL
other	NULL
compounds	NULL
present	NULL
in	NULL
T2	NULL
might	NULL
modulate	NULL
the	NULL
immunosuppressive	NULL
activities	NULL
of	NULL
T2	NULL
so	NULL
that	NULL
it	NULL
becomes	NULL
ineffective	NULL
in	NULL
comparison	NULL
to	NULL
pure	NULL
triptolide	NULL
in	NULL
inhibiting	NULL
T-cell	NULL
activation	NULL
through	NULL
costimulatory	NULL
receptors	NULL
.	NULL

The	NULL
principal	NULL
regulators	NULL
of	NULL
IL-2	NULL
transcriptional	NULL
activation	NULL
operate	NULL
at	NULL
the	NULL
purine-box/ARRE/NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
DNA	NULL
sequences	NULL
(	NULL
11	NULL
)	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
PG490	NULL
inhibits	NULL
purine-box/ARRE/NF-AT	NULL
signaling	NULL
both	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
activation	NULL
and	NULL
also	NULL
at	NULL
the	NULL
level	NULL
of	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

The	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
PG490	NULL
inhibition	NULL
of	NULL
PMA	NULL
+	NULL
ionomycin	NULL
(	NULL
P/I	NULL
)	NULL
-stimulated	NULL
purine-box/NF-AT	NULL
transcriptional	NULL
activation	NULL
is	NULL
~20	NULL
ng/ml	NULL
,	NULL
whereas	NULL
the	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
PG490	NULL
inhibition	NULL
of	NULL
the	NULL
induced	NULL
specific	NULL
purine-box/ARRE/NF-AT	NULL
DNA	NULL
binding	NULL
complex	NULL
is	NULL
~200	NULL
ng/ml	NULL
.	NULL

From	NULL
this	NULL
result	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
PG490	NULL
predominantly	NULL
inhibits	NULL
purine-box/NF-AT	NULL
signaling	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
activation	NULL
after	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
signaling	NULL
involves	NULL
stimulation-induced	NULL
degradation	NULL
of	NULL
cytoplasmic	NULL
IB	NULL
(	NULL
19	NULL
,	NULL
33	NULL
)	NULL
,	NULL
releasing	NULL
p65	NULL
for	NULL
translocation	NULL
from	NULL
the	NULL
cytoplasm	NULL
into	NULL
the	NULL
nucleus	NULL
,	NULL
where	NULL
p65	NULL
interacts	NULL
with	NULL
p50	NULL
and	NULL
binds	NULL
specifically	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
DNA	NULL
sequence	NULL
.	NULL

Following	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
,	NULL
transcriptional	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
regulated	NULL
through	NULL
specific	NULL
phosphorylation	NULL
of	NULL
p65	NULL
at	NULL
several	NULL
distinct	NULL
sites	NULL
(	NULL
34-37	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
PG490	NULL
potently	NULL
inhibits	NULL
the	NULL
expression	NULL
of	NULL
IxBa	NULL
mRNA	NULL
and	NULL
protein	NULL
,	NULL
and	NULL
these	NULL
decreases	NULL
in	NULL
I	NULL
«	NULL
Ba	NULL
protein	NULL
likely	NULL
serve	NULL
to	NULL
increase	NULL
the	NULL
amount	NULL
of	NULL
p65	NULL
released	NULL
for	NULL
translocation	NULL
into	NULL
the	NULL
nucleus	NULL
and	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

Although	NULL
PG490	NULL
causes	NULL
an	NULL
increase	NULL
in	NULL
nuclear	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
PG490	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
at	NULL
a	NULL
step	NULL
after	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

The	NULL
IxBa	NULL
enhancer	NULL
contains	NULL
at	NULL
least	NULL
two	NULL
potential	NULL
binding	NULL
sites	NULL
for	NULL
NF-kB	NULL
(	NULL
88	NULL
)	NULL
.	NULL

We	NULL
hypothesize	NULL
that	NULL
PG490	NULL
inhibits	NULL
IxBa	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
through	NULL
transcriptional	NULL
inhibition	NULL
of	NULL
the	NULL
IxBa	NULL
gene	NULL
,	NULL
probably	NULL
at	NULL
these	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
sites	NULL
.	NULL

We	NULL
extended	NULL
our	NULL
analysis	NULL
of	NULL
PG490	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
by	NULL
demonstrating	NULL
that	NULL
PG490	NULL
inhibits	NULL
the	NULL
PMA-stimulated	NULL
activation	NULL
of	NULL
chimeric	NULL
transcription	NULL
factors	NULL
containing	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
TAl	NULL
and	NULL
TAZ	NULL
transactivation	NULL
domains	NULL
.	NULL

PG490	NULL
inhibits	NULL
PMA-stimulated	NULL
transcriptional	NULL
activation	NULL
through	NULL
the	NULL
TAl	NULL
domain	NULL
,	NULL
which	NULL
is	NULL
highly	NULL
conserved	NULL
between	NULL
humans	NULL
,	NULL
mice	NULL
,	NULL
and	NULL
Xenopus	NULL
,	NULL
and	NULL
extends	NULL
from	NULL
amino	NULL
acid	NULL
521	NULL
to	NULL
the	NULL
C	NULL
terminus	NULL
at	NULL
amino	NULL
acid	NULL
551	NULL
in	NULL
humans	NULL
.	NULL

This	NULL
result	NULL
implies	NULL
that	NULL
a	NULL
target	NULL
of	NULL
PG490	NULL
inhibition	NULL
resides	NULL
within	NULL
these	NULL
31	NULL
amino	NULL
acids	NULL
.	NULL

Within	NULL
TAl	NULL
there	NULL
are	NULL
7	NULL
serines	NULL
,	NULL
which	NULL
are	NULL
predicted	NULL
to	NULL
align	NULL
on	NULL
one	NULL
side	NULL
of	NULL
an	NULL
a	NULL
helix	NULL
and	NULL
form	NULL
a	NULL
polar	NULL
region	NULL
believed	NULL
to	NULL
act	NULL
similar	NULL
to	NULL
acidic	NULL
transcriptional	NULL
activa-tors	NULL
(	NULL
39	NULL
)	NULL
.	NULL

These	NULL
serine	NULL
residues	NULL
are	NULL
potential	NULL
phosphorylation	NULL
sites	NULL
for	NULL
a	NULL
p65	NULL
regulatory	NULL
kinase	NULL
stimulated	NULL
by	NULL
PMA	NULL
.	NULL

Ostrowski	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40	NULL
)	NULL
identified	NULL
a	NULL
serine	NULL
kinase	NULL
activity	NULL
that	NULL
existed	NULL
in	NULL
the	NULL
nucleus	NULL
and	NULL
that	NULL
copurified	NULL
with	NULL
p65	NULL
through	NULL
two	NULL
sequential	NULL
ion-exchange	NULL
purifications	NULL
.	NULL

TNF-a	NULL
stimulates	NULL
phosphorylation	NULL
of	NULL
p65	NULL
on	NULL
Ser-529	NULL
within	NULL
the	NULL
TAl	NULL
domain	NULL
,	NULL
and	NULL
this	NULL
phosphorylation	NULL
contributes	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
transcriptional	NULL
activation	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Kinases	NULL
that	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
include	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
34	NULL
)	NULL
,	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
85	NULL
)	NULL
,	NULL
and	NULL
casein	NULL
kinase	NULL
II	NULL
(	NULL
36	NULL
)	NULL
,	NULL
although	NULL
none	NULL
of	NULL
these	NULL
kinases	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
phosphorylate	NULL
p65	NULL
within	NULL
the	NULL
TAl	NULL
domain	NULL
.	NULL

Nuclear	NULL
coactivator	NULL
proteins	NULL
,	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
and	NULL
p300	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
TAl	NULL
+	NULL
TAZ	NULL
domains	NULL
of	NULL
p65	NULL
(	NULL
41	NULL
)	NULL
and	NULL
contribute	NULL
to	NULL
NF-kB	NULL
transcriptional	NULL
activation	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

From	NULL
our	NULL
results	NULL
,	NULL
we	NULL
have	NULL
developed	NULL
a	NULL
model	NULL
for	NULL
the	NULL
potential	NULL
mechanisms	NULL
of	NULL
PG490	NULL
inhibition	NULL
of	NULL
transcriptional	NULL
activation	NULL
at	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
purine-box/NF-AT	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

We	NULL
present	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
heterodimer	NULL
interacting	NULL
with	NULL
a	NULL
consensus	NULL
13449	NULL
CD28	NULL
,	NULL
TCR	NULL
TNF	NULL
R	NULL
PG490	NULL
Inhibition	NULL
r	NULL
:	NULL
|	NULL
IB	NULL
|—P	NULL
Ms	NULL
hs	NULL
pes	NULL
;	NULL
\	NULL
Translocation	NULL
|	NULL
|	NULL
\	NULL
<	NULL
p	NULL
Purine-box	NULL
TA	NULL
|	NULL
,	NULL
[	NULL
Transcriptional	NULL
Regulator	NULL
9	NULL
AAGGAGGAAAAACTGTT	NULL
Puring-box/ARRE/	NULL
NF-AT	NULL
target	NULL
site	NULL
TGGGACTTTCC	NULL
_	NULL
TATA	NULL
IL-2	NULL
gene	NULL
NF-xB	NULL
site	NULL
Transcription	NULL
IL-2	NULL
mANA	NULL
Translation	NULL
IL-2	NULL
protein	NULL
Secretion	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Schematic	NULL
showing	NULL
postulated	NULL
mechanisms	NULL
of	NULL
PG490	NULL
inhibition	NULL
of	NULL
transcriptional	NULL
activation	NULL
at	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
purine-box/ARRE/NF-AT	NULL
target	NULL
DNA	NULL
sequences	NULL
.	NULL

T-cells	NULL
stimulated	NULL
at	NULL
the	NULL
antigen	NULL
receptor	NULL
and	NULL
through	NULL
costimulatory	NULL
receptors	NULL
initiate	NULL
signaling	NULL
pathways	NULL
that	NULL
lead	NULL
to	NULL
transcriptional	NULL
activation	NULL
at	NULL
the	NULL
purine-box/ARRE/NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
sequences	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

The	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
DNA	NULL
sequence	NULL
from	NULL
the	NULL
mouse	NULL
Ig	NULL
x	NULL
light	NULL
chain	NULL
is	NULL
shown	NULL
.	NULL

PGA490	NULL
inhibits	NULL
NF-KB	NULL
transcriptional	NULL
activation	NULL
at	NULL
a	NULL
step	NULL
after	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
and	NULL
specific	NULL
binding	NULL
of	NULL
the	NULL
p50-p65	NULL
heterodimer	NULL
to	NULL
DNA	NULL
.	NULL

PG490	NULL
also	NULL
inhibits	NULL
purine-box/NF-AT	NULL
transcriptional	NULL
activation	NULL
more	NULL
potently	NULL
than	NULL
it	NULL
inhibits	NULL
induced	NULL
purine-box/ARRE/NF-AT	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

A	NULL
nuclear	NULL
kinase	NULL
that	NULL
regulates	NULL
transactivation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
the	NULL
purine-box	NULL
regulator	NULL
(	NULL
TA	NULL
kinase	NULL
)	NULL
,	NULL
which	NULL
is	NULL
a	NULL
potential	NULL
target	NULL
of	NULL
PG490	NULL
inhibition	NULL
,	NULL
is	NULL
shown	NULL
.	NULL

Other	NULL
potential	NULL
sites	NULL
of	NULL
PG49O	NULL
inhibition	NULL
of	NULL
transcriptional	NULL
activation	NULL
in	NULL
the	NULL
nucleus	NULL
include	NULL
recruitment	NULL
of	NULL
transcriptional	NULL
coactivators	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
or	NULL
p300	NULL
to	NULL
p65	NULL
or	NULL
interactions	NULL
between	NULL
p65	NULL
and	NULL
the	NULL
purine-box	NULL
regulator	NULL
and	NULL
RNA	NULL
polymerase	NULL
II	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
target	NULL
regulatory	NULL
sequence	NULL
,	NULL
and	NULL
the	NULL
purine-box	NULL
transcriptional	NULL
regulator	NULL
interacting	NULL
with	NULL
the	NULL
purine-box/ARRE/	NULL
NF-AT	NULL
target	NULL
sequence	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

Following	NULL
stimulation	NULL
of	NULL
cells	NULL
with	NULL
PMA	NULL
,	NULL
PMA	NULL
+	NULL
ionomycin	NULL
,	NULL
TNF	NULL
,	NULL
or	NULL
other	NULL
NF-	NULL
«	NULL
B-activating	NULL
stimuli	NULL
,	NULL
there	NULL
is	NULL
induced	NULL
degradation	NULL
of	NULL
IB	NULL
,	NULL
releasing	NULL
p65	NULL
for	NULL
translocation	NULL
from	NULL
the	NULL
cytoplasm	NULL
into	NULL
the	NULL
nucleus	NULL
.	NULL

Once	NULL
in	NULL
the	NULL
nucleus	NULL
,	NULL
p65	NULL
combines	NULL
with	NULL
p50	NULL
,	NULL
and	NULL
the	NULL
p50-p65	NULL
heterodimer	NULL
binds	NULL
specifically	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
DNA	NULL
sequence	NULL
.	NULL

We	NULL
postulate	NULL
that	NULL
PG490	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
purine-box/NF-AT	NULL
transcriptional	NULL
activation	NULL
after	NULL
specific	NULL
DNA	NULL
binding	NULL
involves	NULL
inhibition	NULL
of	NULL
regulated	NULL
phosphorylation	NULL
of	NULL
the	NULL
transactivation	NULL
domains	NULL
(	NULL
TA	NULL
)	NULL
of	NULL
each	NULL
transcriptional	NULL
regulator	NULL
by	NULL
a	NULL
nuclear	NULL
kinase	NULL
,	NULL
which	NULL
we	NULL
designate	NULL
the	NULL
TA	NULL
kinase	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Because	NULL
PG490	NULL
at	NULL
higher	NULL
doses	NULL
also	NULL
acts	NULL
to	NULL
inhibit	NULL
the	NULL
induced	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
purine-box	NULL
regulator	NULL
binding	NULL
to	NULL
the	NULL
ARRE/NF-AT	NULL
target	NULL
sequence	NULL
,	NULL
we	NULL
hypothesize	NULL
that	NULL
there	NULL
is	NULL
a	NULL
PGA49O-sensitive	NULL
nuclear	NULL
phosphorylation	NULL
step	NULL
that	NULL
regulates	NULL
specific	NULL
DNA	NULL
binding	NULL
of	NULL
the	NULL
purine-box	NULL
regulator	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
PG490	NULL
in	NULL
inhibiting	NULL
transcriptional	NULL
activation	NULL
in	NULL
the	NULL
nucleus	NULL
after	NULL
specific	NULL
binding	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
DNA	NULL
might	NULL
also	NULL
involve	NULL
interference	NULL
with	NULL
recruitment	NULL
of	NULL
coactivator	NULL
proteins	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
/p300	NULL
or	NULL
inhibition	NULL
of	NULL
interactions	NULL
between	NULL
p65	NULL
and	NULL
RNA	NULL
polymerase	NULL
II	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Our	NULL
identification	NULL
that	NULL
PG490	NULL
effectively	NULL
inhibits	NULL
T-cell	NULL
activation	NULL
and	NULL
IL-2	NULL
gene	NULL
expression	NULL
triggered	NULL
through	NULL
pathways	NULL
that	NULL
are	NULL
resistant	NULL
to	NULL
CsA	NULL
suggest	NULL
therapeutic	NULL
utility	NULL
for	NULL
PG490	NULL
as	NULL
an	NULL
immunosuppressant	NULL
capable	NULL
of	NULL
treating	NULL
chronic	NULL
allograft	NULL
rejection	NULL
and	NULL
also	NULL
graft	NULL
versus	NULL
host	NULL
disease	NULL
.	NULL

Furthermore	NULL
,	NULL
signaling	NULL
through	NULL
members	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
serves	NULL
to	NULL
simultaneously	NULL
activate	NULL
pathways	NULL
of	NULL
inflammation	NULL
involving	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
apoptosis	NULL
involving	NULL
caspases	NULL
.	NULL

The	NULL
balance	NULL
of	NULL
survival	NULL
over	NULL
death	NULL
can	NULL
be	NULL
influenced	NULL
by	NULL
the	NULL
degree	NULL
of	NULL
acti-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
13450	NULL
PG490	NULL
Inhibits	NULL
Purine-box	NULL
/	NULL
NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Transcription	NULL
vation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

The	NULL
antiinflammatory	NULL
effects	NULL
of	NULL
PG490	NULL
involve	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
after	NULL
specific	NULL
binding	NULL
to	NULL
DNA	NULL
,	NULL
and	NULL
this	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
probably	NULL
contributes	NULL
to	NULL
the	NULL
pro-apoptotic	NULL
effects	NULL
observed	NULL
with	NULL
PG490	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Ed	NULL
Lennox	NULL
,	NULL
Glenn	NULL
D.	NULL
Rosen	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Wiedmann	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Tao	NULL
,	NULL
X.	NULL
L.	NULL
,	NULL
Sun	NULL
,	NULL
Y.	NULL
,	NULL
Dong	NULL
,	NULL
Y.	NULL
,	NULL
Xiao	NULL
,	NULL
Y.	NULL
L.	NULL
,	NULL
Hu	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Shi	NULL
,	NULL
Y.	NULL
P.	NULL
,	NULL
Zhu	NULL
,	NULL
Q.	NULL
L.	NULL
,	NULL
Dai	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Zhang	NULL
,	NULL
N.	NULL
Z	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Chin	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

102	NULL
,	NULL
827-832	NULL
2	NULL
.	NULL

Kupchan	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Court	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Dailey	NULL
,	NULL
R.	NULL
,	NULL
Jr.	NULL
,	NULL
Gilmore	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Bryan	NULL
,	NULL
R.	NULL
F.	NULL
(	NULL
1972	NULL
)	NULL
J	NULL
.	NULL

Am	NULL
.	NULL

Chem	NULL
.	NULL

Soc	NULL
.	NULL

94	NULL
,	NULL
7194-7195	NULL
3	NULL
.	NULL

Wei	NULL
,	NULL
Y.	NULL
S.	NULL
,	NULL
and	NULL
Adachi	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Chung-Kuo	NULL
Yao	NULL
Li	NULL
Hsueh	NULL
Pao	NULL
12	NULL
,	NULL
406-410	NULL
4	NULL
.	NULL

Shamon	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Pezzuto	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Graves	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Mehta	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Wangcharoen-trakul	NULL
,	NULL
S.	NULL
,	NULL
Sangsuwan	NULL
,	NULL
R.	NULL
,	NULL
Chaichana	NULL
,	NULL
S.	NULL
,	NULL
Tuchinda	NULL
,	NULL
P.	NULL
,	NULL
Cleason	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Reutrakul	NULL
,	NULL
V.	NULL
(	NULL
1997	NULL
)	NULL
Cancer	NULL
Lett	NULL
.	NULL

112	NULL
,	NULL
118-117	NULL
.	NULL

Kupchan	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Schubert	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1974	NULL
)	NULL
Science	NULL
185	NULL
,	NULL
791-798	NULL
.	NULL

Zheng	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Fang	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Gu	NULL
,	NULL
K.	NULL
X.	NULL
,	NULL
Xu	NULL
,	NULL
L.	NULL
F.	NULL
,	NULL
Gao	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Guo	NULL
,	NULL
H.	NULL
Z.	NULL
,	NULL
Yu	NULL
,	NULL
Y.	NULL
H.	NULL
,	NULL
and	NULL
Sun	NULL
,	NULL
H.	NULL
Z	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Chung-Kuo	NULL
I	NULL
Hsueh	NULL
Ko	NULL
Hsueh	NULL
Yuan	NULL
Hsueh	NULL
Pao	NULL
9	NULL
,	NULL
317-322	NULL
.	NULL

Tao	NULL
,	NULL
X.	NULL
,	NULL
Davis	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
and	NULL
Lipsky	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

84	NULL
,	NULL
1274-1281	NULL
.	NULL

Yang	NULL
,	NULL
S.	NULL
X.	NULL
,	NULL
Xie	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Gao	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Ma	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
and	NULL
Long	NULL
,	NULL
Z	NULL
.	NULL

Z	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Int	NULL
.	NULL

J.	NULL
Immunopharmacol	NULL
.	NULL

16	NULL
,	NULL
895-904	NULL
9	NULL
.	NULL

Tao	NULL
,	NULL
X.	NULL
,	NULL
Cai	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
Lipsky	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

272	NULL
,	NULL
1305-1312	NULL
10	NULL
.	NULL

Tao	NULL
,	NULL
X.	NULL
,	NULL
Davis	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
Hashimoto	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Lipsky	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

276	NULL
,	NULL
816-825	NULL
11	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Avots	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Neumann	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1268	NULL
,	NULL
181-200	NULL
12	NULL
.	NULL

Corthesy	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Kao	NULL
,	NULL
P.	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
20682-20690	NULL
13	NULL
.	NULL

Kao	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
Chen	NULL
,	NULL
L.	NULL
,	NULL
Brock	NULL
,	NULL
G.	NULL
,	NULL
Ng	NULL
,	NULL
J.	NULL
,	NULL
Kenny	NULL
,	NULL
J.	NULL
,	NULL
Smith	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Corthesy	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
20691-20699	NULL
14	NULL
.	NULL

Ting	NULL
,	NULL
N.	NULL
S.	NULL
Y.	NULL
,	NULL
Kao	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
Chan	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Lintott	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
and	NULL
Lees-Miller	NULL
,	NULL
S.	NULL
P.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
2186-2145	NULL
15	NULL
.	NULL

Giffin	NULL
,	NULL
W.	NULL
,	NULL
Torrance	NULL
,	NULL
H.	NULL
,	NULL
Rodda	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Prefontaine	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Pope	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Hache	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Nature	NULL
380	NULL
,	NULL
265-268	NULL
16	NULL
.	NULL

Aoki	NULL
,	NULL
Y.	NULL
,	NULL
Zhao	NULL
,	NULL
G.	NULL
,	NULL
Qiu	NULL
,	NULL
D.	NULL
,	NULL
Shi	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Kao	NULL
,	NULL
P.	NULL
N.	NULL
(	NULL
1998	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

275	NULL
,	NULL
L1164-L1172	NULL
17	NULL
.	NULL

Los	NULL
,	NULL
M.	NULL
,	NULL
Schenk	NULL
,	NULL
H.	NULL
,	NULL
Hexel	NULL
,	NULL
K.	NULL
,	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Droge	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Schulze-Osthoff	NULL
.	NULL

,	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

14	NULL
,	NULL
3731-3740	NULL
18	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Gillespie	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
4472-4481	NULL
g	NULL
O	NULL
go	NULL
~	NULL
22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43.	NULL
.	NULL

Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Mayo	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
,	NULL
Jr.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
784-787	NULL
45	NULL
.	NULL

46.	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
.	NULL

Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunobiology	NULL
198	NULL
,	NULL
116-127	NULL
.	NULL

Cozens	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Yezzi	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Kunzelmann	NULL
,	NULL
K.	NULL
,	NULL
Ohrui	NULL
,	NULL
T.	NULL
,	NULL
Chin	NULL
,	NULL
L.	NULL
,	NULL
Eng	NULL
,	NULL
K.	NULL
,	NULL
Finkbeiner	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Widdicombe	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Gruenert	NULL
,	NULL
D.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Resp	NULL
.	NULL

Crit	NULL
.	NULL

Care	NULL
Med	NULL
.	NULL

10	NULL
,	NULL
38-47	NULL
Aoki	NULL
,	NULL
Y.	NULL
,	NULL
Qiu	NULL
,	NULL
D.	NULL
,	NULL
Uyei	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Kao	NULL
,	NULL
P.	NULL
N.	NULL
(	NULL
1997	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

272	NULL
,	NULL
L272-L284	NULL
Uetsuki	NULL
,	NULL
T.	NULL
,	NULL
Naito	NULL
,	NULL
A.	NULL
,	NULL
Nagata	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Kaziro	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
5791-5798	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

96	NULL
,	NULL
1170-1177	NULL
Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
3805-3817	NULL
Aoki	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Kao	NULL
,	NULL
P.	NULL
N.	NULL
(	NULL
1997	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

284	NULL
,	NULL
424-481	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

41	NULL
,	NULL
1-88	NULL
Haskill	NULL
,	NULL
S.	NULL
,	NULL
Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Tompkins	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Morris	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Yurochko	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sampson-Johannes	NULL
,	NULL
A.	NULL
,	NULL
Mondal	NULL
,	NULL
K.	NULL
,	NULL
Ralph	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
,	NULL
Jr.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
1281-1289	NULL
O'Keefe	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
O'Neill	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
692-694	NULL
.	NULL

Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
695-697	NULL
.	NULL

Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
dos	NULL
Santos	NULL
Silva	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
15576-15584	NULL
.	NULL

Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Okamoto	NULL
,	NULL
S.	NULL
,	NULL
Ishikawa	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Matsushima	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Leu-	NULL
kocyte	NULL
Biol	NULL
.	NULL

56	NULL
,	NULL
554-558	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
,	NULL
Jr.	NULL
(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
649-683	NULL
.	NULL

Zhong	NULL
,	NULL
H.	NULL
,	NULL
Su¥Yang	NULL
,	NULL
H.	NULL
,	NULL
Erdjument-Bromage	NULL
,	NULL
H.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Ghosh	NULL
,	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
Cell	NULL
89	NULL
,	NULL
413-424	NULL
.	NULL

Van	NULL
den	NULL
Berghe	NULL
,	NULL
W.	NULL
,	NULL
Plaisance	NULL
,	NULL
S.	NULL
,	NULL
Boone	NULL
,	NULL
E.	NULL
,	NULL
De	NULL
Bosscher	NULL
,	NULL
K.	NULL
,	NULL
Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Fiers	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Haegeman	NULL
,	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
8285-3290	NULL
.	NULL

Bird	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Schooley	NULL
,	NULL
K.	NULL
,	NULL
Dower	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Hagen	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Virca	NULL
,	NULL
G.	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
82606-82612	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
29411-29416	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Schmidt-Ullrich	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
5048-5049	NULL
.	NULL

Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
dos	NULL
Santos	NULL
Silva	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Altmann	NULL
,	NULL
H.	NULL
,	NULL
Czisch	NULL
,	NULL
M.	NULL
,	NULL
Holak	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
25618-25620	NULL
Ostrowski	NULL
,	NULL
J.	NULL
,	NULL
Sims	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Sibley	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Valentine	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Dower	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Meier	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
and	NULL
Bomsztyk	NULL
,	NULL
K.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
12722-12733	NULL
Gerritsen	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Williams	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Neish	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Moore	NULL
,	NULL
S.	NULL
,	NULL
Shi	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

94	NULL
,	NULL
2927-2932	NULL
Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
Felzien	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Betts	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Leung	NULL
,	NULL
K.	NULL
,	NULL
Beach	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
and	NULL
Nabel	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Science	NULL
275	NULL
,	NULL
528-527	NULL
Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
782-784	NULL
Yang	NULL
,	NULL
Y.	NULL
,	NULL
Liu	NULL
,	NULL
Z.	NULL
,	NULL
Tolosa	NULL
,	NULL
E.	NULL
,	NULL
Yang	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Li	NULL
,	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
Immunopharmacology	NULL
40	NULL
,	NULL
139-149	NULL
Lee	NULL
,	NULL
K.	NULL
Y.	NULL
,	NULL
Chang	NULL
,	NULL
W.	NULL
,	NULL
Qiu	NULL
,	NULL
D.	NULL
,	NULL
Kao	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
and	NULL
Rosen	NULL
,	NULL
G.	NULL
D.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274	NULL
,	NULL
18451-18455	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Immunosuppressant	NULL
PG490	NULL
(	NULL
Triptolide	NULL
)	NULL
Inhibits	NULL
T-cell	NULL
Interleukin-2	NULL
Expression	NULL
at	NULL
the	NULL
Level	NULL
of	NULL
Purine-box/Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T-cells	NULL
and	NULL
NF-	NULL
KB	NULL
Transcriptional	NULL
Activation	NULL
Daoming	NULL
Qiu	NULL
,	NULL
Guohua	NULL
Zhao	NULL
,	NULL
Yosuke	NULL
Aoki	NULL
,	NULL
Lingfang	NULL
Shi	NULL
,	NULL
Anne	NULL
Uyei	NULL
,	NULL
Saman	NULL
Nazarian	NULL
,	NULL
James	NULL
C.-H.	NULL
Ng	NULL
and	NULL
Peter	NULL
N.	NULL
Kao	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:13443-13450.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.19.13443	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/274/19/1	NULL
3443	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
46	NULL
references	NULL
,	NULL
19	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
3443.	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL

